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Abstract  
The human gut contains a dense group of microbes termed the microbiota, which has been 
shown to play a major role in health and disease. Despite significant diversity at species level, the 
microbiota is dominated by only two phyla, the Gram-negative Bacteroidetes and Gram-positive 
Firmicutes. The Bacteroidetes are able to use a wide range of different complex glycans from both 
dietary and host sources. Bacteroidetes express groups of co-regulated, cell envelope associated 
proteins termed polysaccharide utilisation loci (PULs). Each PUL is specific for a different glycan with 
some species of Bacteroides, one of the major genera of the gut, encoding >100 predicted PULs. 
PULs encodes enzymes, binding proteins, a regulator and a transporter which are localised to the 
outer-membrane or periplasm for the complete degradation and transport of the target glycan. 
Following initial, partial degradation of the target polysaccharide at the cell surface, the resulting 
oligosaccharides are transported into the periplasm. This process involves an outer membrane 
complex consisting of a substrate binding lipoprotein (SusD-like) and a β-barrel TonB dependent 
transporter (SusC-like). This SusCD transporter complex is vital to utilisation of glycans by 
Bacteroidetes as oligosaccharide breakdown to monosaccharides occurs in the periplasm. Despite 
the importance of this process to microbiota function, the mechanism of SusCD function is unclear. 
How extracellular substrate binding by the SusD-like protein is coupled to import by SusC is unknown 
as other classes of TonB dependent transporters do not have a partner lipoprotein. 
A SusCD complex with two auxiliary lipoproteins, BT2261-4, was expressed natively and 
purified directly from Bacteroides thetaiotaomicron. The X-ray crystal structure shows the SusC 
transporters form a homodimer with a SusD-like binding protein capping each barrel like a lid. The 
structure also shows a linear peptide bound at the interface of the SusC and SusD proteins via 
interactions with the peptide backbone. Expression levels of the BT2261-4 complex indicated that 
the proteins were required for growth under nutrient stress conditions which suggests a possible 
role in peptide scavenging.  
A classical glycan targeting SusCD complex, BT1762-3 from the Bacteroides thetaiotaomicron 
levan PUL, was targeted by adding a His-tag to the genomic copy of the SusD-like binding protein 
BT1762. The His-tag allowed purification of the BT1762-3 complex which led to two further SusCD 
structures; apo and with a levan oligosaccharide bound. BT1762-3 has the same overall 
conformation as the peptide importing SusCD suggesting the dimeric SusC transporter and SusD 
protein ‘cap’ general structure is conserved across SusCD complexes. MD simulations and 
electrophysiology experiments allowed us to propose a model for SusCD function where the SusD-
like binding protein sits on top of the SusC-like transporter like a lid and is able to open like a pedal 
bin to allow oligosaccharide binding and uptake.    
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Chapter 1 – Introduction 
1.1 Human Gut Microbiota  
The human intestine hosts a microbial population consisting of trillions of organisms with a 
biomass of approximately 1.5 kg (Xu and Gordon, 2003). The vast community of microbes is 
dominated by bacterial species but also includes eukaryotes and archaea (Eckburg et al., 2003). 
Some of the micro-organisms are permanent ‘residents’ of the gut and others are just passing 
through (Savage, 1977). This microbial population is generally termed the human gut microbiota 
(HGM) and forms a symbiotic relationship with the host, in which the host provides nutrients and 
the symbionts positively affect the health of the host. From birth the HGM develops alongside the 
host, influenced by changes in the human diet from infancy through to adulthood (Ottman et al., 
2012).  
1.1.1 Composition of the Human Gut Microbiota 
Development of high-throughput sequencing techniques has enabled the complex HGM 
composition to be analysed where previously it was necessary to culture each species for 
identification (Metzker, 2010). Such advances led to the Human Microbiome Project (HMP) in 2008 
with the aim to characterise the human microbiome, including the identification of species within 
the gut microbiota. The Human Microbiome Project (HMP) and Metagenomics of the Human 
Intestinal Tract consortium (MetaHIT) studies use stool samples to analyse the HGM composition as 
the technique is non-invasive unlike alternative methods such as endoscopy. However, stool samples 
may not give an accurate representation of the overall gut microbiota, containing mostly species 
from the distal end of the colon. Mice studies using humanised microbiota have shown phylogenetic 
diversity between the early and late gastro-intestinal (GI) tract compared with mid GI tract where 
diversity is reduced (Gu et al., 2013). Differences are believed to be due to variations in oxygen along 
the GI tract, where obligate anaerobes were found in locations more likely to provide anaerobic 
conditions (Gu et al., 2013).  
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Figure 1.1 Human gut microbiota composition through lifetime 
Global overview of the relative abundance of key phyla of the HGM in different stages of life. 
Measured by 16S RNA sequencing (16S) or metagenomic approaches (DNA). From Ottman et al., 
2012.  
 
The HGM is established at birth, starting as a dynamic community dominated by 
Bifidobacterium spp. and differs significantly between breast-fed and formula-fed babies (Figure 1.1) 
(Schwartz et al., 2012). The HGM community stabilises during the first 2-3 years (Koenig et al., 2011; 
Scholtens et al., 2012). Diversity of the HGM increases as we mature (Scholtens et al., 2012), 
reaching peak complexity in adulthood, but dominated by two bacterial phyla Bacteroidetes and 
Firmicutes (Rajilic-Stojanovic et al., 2009). Each individual’s HGM reaches an equilibrium which 
remains relatively stable during a healthy adult’s life (Ottman et al., 2012). The exact species 
composition is highly variable between individuals, but the overall phylogenetic profile has been 
categorised during a MetaHIT study into three well-balanced states termed enterotypes which were 
based on the three dominant genera of the HGM; Bacteroides, Prevotella and Ruminococcus 
(Arumugam et al., 2011). However, it has been argued that this is an oversimplification of the highly 
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complex HGM communities (Knights et al., 2014). During later stages of life the microbiota 
composition returns to being less diverse and more dynamic, characterised by higher Bacteroidetes 
to Firmicutes ratio, increased Proteobacteria and decreased Bifidobacterium (Figure 1.1) (Biagi et al., 
2010).   
Results of HGM identification studies have shown incredible diversity at the species level 
with thousands of individual species present but remarkably, over 90 % of the HGM are from only 
two phyla; Bacteroidetes and Firmicutes (Figure 1.2) (Rajilic-Stojanovic et al., 2009; Qin et al., 2010). 
Bacteroides is the most abundant and variable genus (Salyers, 1984; Arumugam et al., 2011).  
 
 
Figure 1.2 Diversity of phyla and genera within the HGM of healthy individuals.  
A box plot showing the thirty most abundant genera of the human HGM. Inset shows abundance at 
the phylum level. Genus and phylum level abundances were calculated using reference genome-
based mapping using 85% and 65% cutoff, respectively. Samples were taken from 39 individuals 
from 6 nationalities. From Arumugan et al., 2011. 
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The HGM composition is highly sensitive to any change in conditions such as diet or invasion 
of enteric pathogens (Lupp et al., 2007; David et al., 2014). The resilience of the HGM varies 
between individuals with some patients returning to the original state and others reaching a new 
stable state after a disturbance (Lichtman et al., 2016; Sonnenburg et al., 2016). Most data regarding 
the HGM composition is in context of antibiotic response in humans living in urban areas which have 
reduced HGM diversity than populations living traditional rural lifestyles (Yatsunenko et al., 2012; 
Martinez et al., 2015). A recent study of the Hadza hunter-gatherers of Tanzania showed annual 
reconfiguration of the HGM in which some taxa become completely undetectable but reappear in 
later seasons (Smits et al., 2017). Interestingly, the most seasonally volatile species of bacteria in the 
Hadza HGM are missing from industrialised populations, in particular Prevotellaceae sp. of the 
Bacteroidetes phylum (Smits et al., 2017).  
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1.1.2 Importance of glycan fermentation by the HGM in health and disease 
Humans use fats, proteins, simple sugars and starch which are absorbed in the early GI tract. 
Polysaccharides and oligosaccharides, commonly referred to as fibre, provide the main source of 
nutrients for the HGM. Members of the HGM ferment the complex carbohydrates into metabolites 
which interact with other microbes and the host. Short chain fatty acids (SCFAs) are the main 
metabolites produced during glycan fermentation and provide many of the microbiota-associated 
benefits to the host (Figure 1.3). SCFAs provide up to 70 % of the energy required by epthithelial 
cells of the colon (colonocytes) (Roy et al., 2006).  The three most abundant SCFAs are generally 
found in the human gut at a combined concentration of 50 – 100 mM (Louis et al., 2014). Generally, 
propionate is produced by Bacteroidetes, while butyrate is generated by Firmicutes such as 
Roseburia species and also by Bifidobacterium from the Actinobacteria phylum (Reichardt et al., 
2014).  
Acetate, the most abundant SCFA, is absorbed in the colon and metabolised by the liver and 
muscles providing up to 2 kcal/g of energy for the host (Kien, 1996; Topping and Clifton, 2001). 
Acetate has also been shown to aid prevention of enteropathic infection through stimulation of the 
intestinal epithelium (Fukuda et al., 2011). Once in circulation acetate can cross the blood-brain 
barrier where it has been found to reduce appetite via a central homeostatic mechanism (Frost et 
al., 2014). Acetate has been found to inhibit the action of histone deacetylases, although only in 
activated T-cells of the human immune system (Park et al., 2015).  
Butyrate has been linked to colorectal cancer inhibition by acting as a histone deacetylase 
inhibitor in cancerous cells, altering expression of genes involved in cell proliferation, differentiation 
and apoptosis. However, butyrate can be used as an energy source and stimulate growth for non-
cancerous cells. This dissonance is referred to as the butyrate paradox (Lupton, 2004). A recent 
study has shown depletion of butyrate-producing microbes through antibiotic use increased the 
levels of free oxygen in the lumen of the gut, which allowed harmful bacteria such as Escherichia coli 
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(E. coli) and Salmonella enterica to multiply, leading to dysbiosis (Byndloss et al., 2017). Butyrate 
helps restrict growth of such oxygen dependent pathogens by signalling to the cells lining the gut to 
maximise oxygen consumption which depletes the oxygen levels in the lumen (Byndloss et al., 2017). 
Propionate delays gastric emptying which promotes satiety in the host and thus is believed to act as 
an anti-obesity factor (Arora et al., 2011). 
 
 Figure 1.3 Effects of SCFAs produced by the HGM on host cells  
Fermentation of carbohydrates in the anaerobic environment of the gut produces SCFAs, the most 
abundant of which are butyrate, propionate and acetate. All three SCFAs act as histone deacetylase 
(HDAC) inhibitors in different cell types to produce different downstream effects. Butyrate can be 
used by colonocytes as an energy source and has been shown to inhibit cancer cell proliferation. 
Propionate and butyrate can force differentiation of naïve T cells into Treg (regulatory) cells which 
produce IL-10. Acetate is metabolised by liver and muscle cells but is also able to cross the blood-
brain barrier where it induces satiety signals. Adapted from Hoeppli et al., 2015 by Jonathon Briggs 
(Thesis 2016). 
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When dietary fibre is limited, microbes can utilise less energetically favourable sources such 
as amino acids from dietary or endogenous proteins (Cummings and Macfarlane, 1991). These 
substrates lead to reduced fermentation although SCFAs and some branched-chain fatty acids can be 
produced (Cummings and Macfarlane, 1991). The resulting metabolites have been linked to insulin 
resistance in host cells (Newgard et al., 2009).  
Reduced dietary fibre has been associated with thinner colonic mucus by several studies 
(Brownlee et al., 2003; Hedemann et al., 2009; Earle et al., 2015). In the absence of fibre in the diet, 
at least one common member of the HGM (Bacteroides thetaiotaomicron; B. theta) can shift from 
dietary polysaccharides to mucus glycan metabolism (Sonnenburg et al., 2005). A recent study 
investigated the effect of chronic and intermittent dietary fibre depravation on microbiota 
physiology and the resulting effects on the mucus barrier (Desai et al., 2016). The experiments 
involved assembling a synthetic gut microbiota in germ-free mice of 14 commensal members of the 
HGM. This study showed that a diet deficient of complex plant glycans (fibre) initiated the synthetic 
gut microbiota to feed on the colonic mucus layer (Figure 1.4). This increased susceptibility of the 
mice to Citrobacter rodentium, a murine pathogen that models human enteric E. coli infection, as 
the mucus layer is a primary barrier against invading pathogens (Desai et al., 2016). 
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Fibre-rich (FR) Diet Fibre-free (FF) Diet 
FR/FF Diet 
(no commensal microbiota) 
 
 Figure 1.4 Model of how a fibre-deprived gut microbiota mediates degradation of the colonic 
mucus barrier and heighted pathogen susceptibility  
Schematic diagram showing a model of the balance between fibre degradation and mucus 
degradation in fibre-rich (FR) diet-fed mice. The fibre-free (FF) diet leads to proliferation of mucus-
degrading bacteria and degradation of the colonic mucus layer by the microbiota which leads to 
more severe colitis by C. rodentium. Adapted from Desai et al. 2016 
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1.1.3 Manipulation of the HGM  
Abnormalities or imbalance in the HGM composition (Sekirov et al., 2010) has been 
associated with several disease states including; inflammatory bowel disease (IBD) (Ni et al., 2017),  
obesity (Sonnenburg and Backhed, 2016; Martinez et al., 2017), hypertension (Marques et al., 2017), 
cardiovascular disease (Lau et al., 2017) and some types of cancer (Chen et al., 2017). The dysbiosis 
may be caused by increased levels of potentially harmful micro-organisms or an increased flux 
through harmful metabolic pathways (Koropatkin et al., 2012). Therefore manipulation of the HGM 
composition can be used to benefit the health of the host.  
There are two main treatments for manipulation of the HGM; probiotics and prebiotics. 
Probiotics are live micro-organisms which can provide a health benefit to the host when 
administered in adequate amounts (Hill et al., 2014). Prebiotics are complex carbohydrates which 
enrich a limited number of beneficial bacteria of the HGM (Gibson and Roberfroid, 1995). The 
definition was later updated to include that the prebiotic must not restrict gastric acidity and must 
not be absorbed by the host (Gibson et al., 2004). Fructo-oligosaccharides (FOS) and galacto-
oligosaccharides (GOS) are used as prebiotics although new research suggests a much wider range of 
glycans may produce similar positive health benefits (Chapla et al., 2012; Lefranc-Millot et al., 2012). 
One potential health benefit of prebiotics is related to sepsis. During early infancy, sepsis causes an 
estimated 1 million deaths worldwide every year and current there is no preventative medicine 
available (Thaver and Zaidi, 2009). A recent study of 4,556 newborns in rural India showed a 
reduction in the incidence of sepsis of 40 % when given a prebiotic (FOS) and probiotic (Lactobacillus 
plantarum) combined treatment (Panigrahi et al., 2017).  
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1.2 Outer Membrane Proteins in Gram-negative Bacteria 
Bacterial survival in any niche, such as within the HGM, requires import of nutrients. The 
additional membrane layer of Gram-negative bacteria, termed the outer membrane (OM), serves as 
a selective barrier (Figure 1.5) (Raetz and Whitfield, 2002; Nikaido, 2003). Import of required 
nutrients and solutes across this obstacle is essential for bacterial survival. Movement across the 
outer membrane is mediated by protein channels which can be divided into three classes; general 
porins, substrate-specific channels and active transporters (Nikaido, 2003).  
  
Figure 1.5 Structure of Gram negative bacteria cell walls  
The cell wall of Gram negative bacteria consists of an inner and outer membrane with a 
peptidoglycan layer in periplasm between. The outer membrane is asymmetrical; the inner leaflet 
consists of phospholipids (similar to the inner membrane) and the outer leaflet is predominantly 
lipopolysaccharides (LPS). Figure from  Raetz and Whitfield, 2002. 
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1.2.1 General Porins 
Passive diffusion across the OM via non-specific porins is utilised by many Gram-negative 
bacteria. Early characterisation of such proteins from E. coli (eg. OmpF and OmpC) formed the basis 
of our understanding of many porins and so they are often referred to as ‘classical porins’ (Nikaido, 
2003).  These form transmembrane channels of anti-parallel β-barrel strands which often self-
associate and function as homotrimers (Figure 1.6) (Cowan et al., 1992; Schulz, 2002; Baslé et al., 
2006; Yamashita et al., 2008). A common feature of classical porins is the restriction of the channel 
by loop 3 (L3) which folds back into the barrel (Figure 1.6).  The water-filled pores, which are formed 
by these proteins in the OM, allow substrates to diffuse across the membrane driven by the 
concentration gradient.  Although non-specific, the proteins have a preference for small (<600 Da) 
hydrophilic substrates with charge (Delcour, 2003). OmpF and OmpC show a preference for cations 
but some classical porins, such as PhoE, prefer anions. Many antibiotics gain access to cells via non-
specific porins and mutations of loop 3 have been associated with antibiotic resistance (Pages et al., 
2008; Delcour, 2009).  
 
Figure 1.6 Structure of OmpC a non-specific porin from E. coli 
A: Cartoon representation of the OmpC trimer structure (PDB ID 2J1N) within the outer membrane 
(OM). The individual monomers are coloured purple, orange and teal. B: The OmpC trimer shown 
from outside the cell, highlighting loop 3 (L3) which restricts the size of the barrel.    
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1.2.2 Substrate-specific Porins 
Diffusion via general non-specific channels is no longer efficient for substrates which are 
present at low (micromolar) extracellular concentrations. Due to this, substrate-specific porins are 
especially widespread in bacteria which can survive in nutrient-poor environments such as 
Pseudomas spp. (Eren et al., 2012). Substrate specific channels form very similar structures to their 
non-specific counterparts, with a β-stranded barrel forming a passage across the membrane (Figure 
1.7). However, specific porins such as the maltose channel LamB (Szmelcman and Hofnung, 1975; 
Schirmer et al., 1995) and nucleoside channel Tsx (Hantke, 1976) from E. coli have low-affinity 
(micromolar to millimolar) binding sites to allow efficient diffusion of specific molecules.  
 
 
Figure 1.7 Structure of a substrate-specific maltose channel LamB from E. coli 
A: Cartoon representation of the LamB trimer structure (PDB ID 1MAL) within the outer membrane 
(OM). The individual monomers are coloured orange, green and blue. B: The LamB trimer shown 
from outside the cell.   
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1.2.3 TonB Dependent Transporters 
Active transport across the OM is complicated by the lack of ATP in the periplasm and there 
is no membrane potential across the OM. Therefore primary (coupled to ATP hydrolysis) and 
secondary active transporters commonly found in the inner membrane (IM) or Gram positive 
bacteria, such as the widely distributed major facilitator superfamily (MFS) transporters, cannot 
function in the OM (Pao et al., 1998). To circumvent these problems Gram negative bacteria use 
TonB dependent transporters (TBDTs) which exploit energy from the proton motive force of the IM 
to drive transport across the outer membrane of Gram-negative bacteria. The TonB-ExbB-ExbD 
protein complex in the IM is required for energy transduction according to a mechanism that is still 
not clear (Sean Peacock et al., 2005; Postle, 2007; Celia et al., 2016). Early TBDT structures were of 
FhuA (Ferguson et al., 1998) and FepA (Buchanan et al., 1999), from E. coli and involved in iron-
siderophore acquisition (Figure 1.8A and B). These structures highlighted the common features of 
TBDTs; a 22 stranded β-barrel monomer with an N-terminal plug domain (Noinaj et al., 2010).  
Upon ligand interaction with the transporter the TBDT-TonB interaction is mediated by the 
conserved N-terminal ‘TonB box’ amino acid sequence of the TBDT and the C-terminal periplasmic 
domain of TonB (Figure 1.8 C and D). However, the mechanism which allows to TonB to ‘remodel’ 
the plug domain of the TBDT is not understood (Hickman et al., 2017). It is widely accepted that the 
plug domain must undergo a conformational change to allow for import of the substrate. However, 
the extent of the conformational change, including the possibility of the plug being completely 
removed from the barrel, is not known (Noinaj et al., 2010).  
TBDTs have been identified which transport a wide range of vital nutrients such as 
maltodextrin (MalA), sucrose (SuxA), metallo-organic compounds including vitamin B12 (BtuB) and 
haem (HasR and HemR) (Schauer et al., 2008; Noinaj et al., 2010). TBDTs are essential for cell 
survival, therefore they are considered a virulence factor in pathogenic bacteria (Perkins-Balding et 
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al., 2004; Garcia et al., 2011; Noinaj et al., 2012). Some TBDTs are also exploited for cell entry by 
colicins and phage (Cascales et al., 2007).  
 
 
Figure 1.8 Structure and Mechanism of TonB Dependent Transporters 
A: Cartoon representation of the E. coli TBDT FepA (PDB ID 1FEP) shown from the side within the OM. 
The N-terminal plug domain is coloured purple. B: FepA transporter viewed from the outside of the 
cell showing occlusion of the channel by the plug domain (purple). C: Schematic representation of 
TonB-dependent vitamin B12 transport by BtuB in E. coli. Peptidoglycan is labelled PG. (i) The channel 
of BtuB is occluded by the N-terminal plug domain. (ii) The binding of vitamin B12 induces a 
conformational change of the plug domain, releasing the Ton box into the periplasmic space where is 
forms a complex with the C-terminal domain of TonB. The N-terminal transmembrane helix of TonB 
(purple cylinder) forms a complex with ExbB and ExbD (grey cylinders) in the inner membrane (OM). 
(ii) Linkage of the OM and IM via the TonB – TonB box complex is thought to induce partial or 
complete unfolding of the plug domain to allow transport. D: Close-up of the interactions between 
TonB (purple) and the TonB box of BtuB (blue). Figure labelled C and D from Hickman et al. 2017.   
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1.3 Polysaccharide Utilisation by Bacteroidetes  
Bacteroidetes are Gram-negative, rod-shaped, anaerobic bacteria and one of the two 
dominant phyla of the HGM (Rajilic-Stojanovic et al., 2009). Bacteroidetes are of particular interest 
in regards to human health due to their capacity to use a wide range of glycans as a carbon source. 
Indeed a recent study showed that only two species of Bacteroides could between them use all 
major dietary and host derived polysaccharides (Martens et al., 2011).  
1.3.1 Polysaccharide Utilisation Loci 
Bacteroidetes express multi-protein systems to efficiently use many different complex 
carbohydrates. The genes encoding these proteins are organised in co-regulated Polysaccharide 
Utilisation Loci (PULs) (Bolam and Koropatkin, 2012). PULs have been identified in every human gut 
Bacteroidetes sequenced to date as well as many environmental species (Grondin et al., 2017b). 
PULs have been found targeting every known naturally occurring glycan except cellulose 
(Sonnenburg et al., 2005; Xu et al., 2007; Martens et al., 2011).  
Early characterisation of the first PUL components by the Salyers lab (Salyers et al., 1977; 
Anderson and Salyers, 1989b) led to the identification of a locus in Bacteroides thetaiotaomicron (B. 
theta) targeting starch glycans which was subsequently named the Starch Utilisation System (Sus, 
Figure 1.9) (Shipman et al., 1999).  The PUL encodes eight cell-envelope associated proteins 
SusRABCDEFG for the binding, degradation and import of starch molecules (Tancula et al., 1992; 
D'Elia and Salyers, 1996). Target polysaccharides are bound by surface located lipoproteins SusD, 
SusE and SusF with initial degradation carried out by SusG, a glycoside hydrolase family 13 (GH13) α-
amylase lipoprotein (Anderson and Salyers, 1989a; Shipman et al., 1999). The resulting 
oligosaccharides are then imported to the periplasm via SusC, a TBDT (Reeves et al., 1996). The 
malto-oligosaccharides are then further digested in the periplasm by a debranching neopullanase 
GH13 enzyme SusA and a GH97 α-glucosidase enzyme SusB  (Anderson and Salyers, 1989a).The 
periplasmic maltose is sensed by the inner membrane spanning SusR, upregulating the Sus proteins 
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and the simple sugars are imported into the cytoplasmic space through an undefined transporter 
(D'Elia and Salyers, 1996). The Sus system is essential for growth on amylose, amylpectin and 
pullulan (Tancula et al., 1992). 
 
Figure 1.10 Overview of the Starch utilisation system (Sus) from B. theta 
Starch is bound to the cell surface by outer membrane lipoproteins SusDEF and digested into 
oligosaccharides by an outer membrane bound glycoside hydrolase (GH) SusG. The malto-
oligosaccharides are transported into the periplasm via SusC a TBDT. Two further GHs in the 
periplasm break down the oligosaccharide into maltose and glucose. The monosaccharide is 
transported into the cytoplasm via an unknown transporter. Transcription of the SusR inner 
membrane spanning receptor occurs independently of the rest of the locus. When SusR senses 
the disaccharide maltose, this induces the PUL and upregulates expression of the other proteins. 
Figure from Foley et al. 2016.  
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PULs have been characterised for a diverse range of substrates including xyloglucan 
(Larsbrink et al., 2014), arabinoxylan (Rogowski et al., 2015), α-mannan (Cuskin et al., 2015), inulin 
(Sonnenburg et al., 2010) and rhamnogalacturonan-II (Ndeh et al., 2017). The number of binding 
proteins and enzymes involved generally increases with the complexity of the glycan target. Several 
PULs targeting highly decorated glycans include two SusCD pairs. All PULs encode the following; a 
SusC-like TBDT alongside a SusD-like binding protein, at least one endo-acting surface-located 
enzyme and a membrane spanning sensor/regulator (Bolam and Koropatkin, 2012). All identified 
PULs are expected to function as Sus-like systems (Foley et al., 2016). 
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1.3.2 Levan Utilisation by Bacteroides thetaiotaomicron 
 The B. theta genome includes 88 predicted PULs of which 20 have been characterised. One 
such well-understood PUL targets levan polysaccharides. Levan is comprised of β,2-6 linked fructose 
units, often with some β2-1 branches, and is produced extracellularly from sucrose by many 
bacterial species including Bacillus (Kekez et al., 2015), Erwinia (Keith et al., 1991), Pseudomonas 
(Jathore et al., 2012), and Zymomonas (Silbir et al., 2014). Levans are also produced by some plants, 
including some that are components of the human diet such as wheat and barley (Van den Ende, 
2013). 
As with the Sus system, the levan PUL of B. theta encodes all the proteins required for 
binding, degrading and importing the target glycan (Figure 1.10). The PUL includes three enzymes, 
BT1759, BT1760 and BT1765, from glycoside hydrolase family 32 (GH32) which are specific to 
fructans (Cantarel et al., 2009). The cell-surface exposed BT1760 is essential for growth of B. theta 
on levan polysaccharides (Sonnenburg et al., 2010). A fourth GH32 BT3082, found in isolation in the 
B. theta genome, is also upregulated in response to levan (Sonnenburg et al., 2010).    
A schematic model of levan utilisation is shown in Figure 1.10. Levan polysaccharides are 
recognised by an extracellular surface glycan binding protein (SGBP) BT1761 and degraded by the 
endo-acting GH32 BT1760 (Sonnenburg et al., 2010; Mardo et al., 2017). The resulting 
oligosaccharides are bound by the SusD-like BT1762 and imported by the SusC-like BT1763. Further 
breakdown of the levan oligos occurs in the periplasm mediated by BT1759GH32 and BT3082GH32. The 
free monomeric fructose is recognised by the periplasmic domain of the hybrid two component 
system (HTCS) sensor BT1754 resulting in upregulation of the PUL (Sonnenburg et al., 2010). 
Fructose is then likely imported by the inner membrane MFS transporter (BT1758) into the 
cytoplasm and passed along the glycolytic pathway after phosphorylation by the fructokinase 
BT1757 (Bolam and Sonnenburg, 2011).  
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Figure 1.10 Model for levan utilisation by B. theta A: Organisation of genes from the levan PUL; 
arrows shown to scale with the direction of the arrow indicating gene orientation. Proteins of 
unknown function are shown in grey B: Model of levan utilisation. Proteins coloured as with genes in 
A. Levan is bound by the SGBP BT1761 and partially digested by BT1760, an extracellular endo-acting 
GH32. The oligosaccharides are then bound and imported by the SusCD pair BT1762-3. In the 
periplasm the oligosaccharides are further degraded by the GH32 exo-acting BT1759 and BT3082. 
Free fructose binds the periplasmic domain of BT1764 HTCS sensor which activates the protein and 
results in upregulation of the PUL. Fructose monosaccharides are imported into the peripasm via the 
BT1758 importer and BT1757 fructokinase phosphorylates the sugar sending it along the glycolytic 
pathway.  
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1.3.3 SusC Homologues 
Since the majority of enzymes encoded by PULs are expressed in the periplasm, the SusC-like 
transporters have adapted to import a very wide range of glycans with varying sizes, sugars, linkages, 
charges and side chains (Porter and Martens, 2017). The SusC homologues are predicted to be 22-
stranded β-barrel TonB dependent transporters (TBDTs) (Shipman et al., 2000). SusC homologue 
domain predictions from Pfam (Finn et al., 2014), SMART (Letunic et al., 2012) and InterPro (Mulder 
and Apweiler, 2008) databases show the conserved N-terminal TonB box and plug domain with the 
remaining part of the polypeptide forming the barrel of the transporter (Figure 1.12). Fully 
characterised TBDTs generally transport small conserved substrates such as iron-siderophores 
(Section 1.2.4), therefore the mechanisms which allow the SusC-like proteins to function are 
completely unknown. Many SusC homologues also show a domain of unknown function (DUF4480) 
at the N-terminus before the TonB box, which is not found in any other TBDTs (Figure 1.11).  
 
 
Figure 1.11 Protein domain predictions for BT1763 SusC homologue 
BT1763SusC domains predicted by Pfam, SMART and InterPro databases. Numbers represent the 
residues of the full length protein sequence.   
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1.3.4 SusD Homologues 
The prototypical Sus system requires SusD to bind starch to the cell surface which was 
shown using 14C-starch binding assays with whole bacteria under aerobic conditions which prevent 
transport of the substrate into the cells (Shipman et al., 2000). More recent studies have used 
isothermal titration calorimetry (ITC) to measure binding of specific substrates to SusD homologues 
(Koropatkin et al., 2008; Sonnenburg et al., 2010).  
The structure of SusD was solved both with and without substrate in 2008 (Koropatkin et al., 
2008). The protein was expressed in E. coli without the lipid anchor and the structure does not 
include the first 16 residues which likely form a flexible link between the globular protein and the 
lipid anchor. The structure contains 22 α-helices, 8 of which form 4 helix-turn-helix tetratricopeptide 
repeats (TPRs) packing together to produce a right-handed superhelix (Allan and Ratajczak, 2011). 
This motif is structurally conserved between all SusD homologue structures in the PDB and may act 
as a scaffold for the overall protein structure which is more variable (Bolam and Koropatkin, 2012). 
TPRs have also been implicated in facilitating protein-protein interactions (Allan and Ratajczak, 
2011). There is evidence that the SusC and SusD form a complex in the outer membrane, based on 
formaldehyde crosslinking experiments and proteolytic tests showing the proteins are more 
sensitive to degradation in strains lacking the partner SusC or SusD (Shipman et al., 2000; Cho and 
Salyers, 2001). The interaction between SusC and SusD has been predicted to be via the region 
surrounding TPR1 (Bakolitsa et al., 2010). It has also been suggested that SusD could be required to 
mediate interactions between the cell surface Sus proteins in addition to binding large starch 
molecules (Cameron et al., 2014). Dynamic interactions could be facilitated by TPR 1/2 of SusD which 
could position SusD for oligosaccharide binding from other Sus lipoproteins and allow transfer of the 
substrates to the SusC (Figure 1.12) (Bolam and Koropatkin, 2012). Recent live-cell super-resolution 
imaging has shown the polymeric starch substrate initiates the co-localisation of the OM Sus 
proteins (Karunatilaka et al., 2014).   
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Starch recognition by the canonical SusD is shape-dependent with preference for the curved 
α 1,4-linked glucose over its linear counterpart (Koropatkin et al., 2008). Comparison of the apo- and 
ligand-bound structures of SusD show a conformational change is required to produce an arched 
hydrophobic surface of tryptophans and tyrosines complementary to the helical oligosaccharides. 
This was consistent for maltotriose, maltoheptose and β-cyclodextran which were all shown to be 
bound by SusD (Koropatkin et al., 2008). However the only other SusD homologue structure solved 
with and without ligand, BT1043 which targets host mucin O-glycans, shows the binding site in the 
same location but does not have any conformational change upon substrate binding (Koropatkin et 
al., 2009).  
 
Figure 1.12 Model for SusCD interactions in 
the outer membrane 
SusD is coloured blue with 4 α-helices which 
form TPR1 and TPR2 coloured purple. 
Maltoheptaose bound to SusD is shown as 
sticks. The interaction between SusC and SusD 
is predicted to occur in the area including 
TPR1 and TPR2. SusD is thought to ‘deliver’ 
oligosaccharides to the SusC for transport 
across the membrane. Figure from Bolam and 
Koropatkin, 2012.  
  
SusC homologues and often the SusD-like partner protein are essential for nutrient 
acquisition by Bacteroidetes. However the import system has not been characterised and the 
coupling of substrate binding to import is not understood.  
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1.4 Research Objectives 
The main aim of this PhD project was to solve the structure of a SusC homologue, 
ideally in complex with its cognate SusD. Preliminary work using recombinant expression in 
E. coli was unsuccessful therefore a protocol for endogenous expression and purification of 
Bacteroides outer membrane proteins (OMPs) needed to be developed. The primary focus 
was to identify highly expressed OMPs and purify proteins of interest in sufficient quantities, 
directly from B. theta, for structural studies (Chapter 3). A further objective was to purify 
and obtain a structure for a specific SusC homologue, BT1763 from the levan PUL, to provide 
insight into glycan acquisition by B. theta (Chapter 4).    
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Chapter 2 - Materials and Methods 
2.1. Bacterial Strains and Mutants 
All bacterial strains are listed in Table 2.1 and mutants produced during this study are in bold.  
Name Genotype Features Description 
BL21 (DE3) F- dcm ompT hsdS(rB- mB-) gal (DE3) E. coli strain optimised for protein 
expression using a T7 promoter. 
Routinely used to over-express 
recombinant proteins (Studier & 
Moffat, 1986) 
TUNER (DE3) F– ompT hsdSB (rB– mB–) gal dcm 
lacY1 (DE3) 
As above for BL21 with added lac 
permease mutation to allow uniform 
permeation of IPTG across cells. 
Linear correlation between IPTG 
concentration and protein expression 
level (Novagen) 
Top10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
ɸ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara, leu)7697 galU galK 
rpsL (STRR) endA1 nupG λ- 
E. coli routinely used for cloning and 
plasmid propagation (Invitrogen) 
CC118 λ-pir Δ(ara-leu) araD ΔlacX74 galE galK 
phoA20 thi-1 rpsE rpoB argE (Am) 
recA1 λpir 
E. coli routinely used for cloning and 
plasmid propagation of pExchange-
tdk (Herrero et al. 1990) 
S17.1 λ-pir recA pro hsdR RP4-2 
(Tc::Mu;Km::Tn7) ( λ pir) 
E. coli strain used for conjugation of 
pExchange-tdk into B. theta  
(Skorupski and Taylor 1996) 
Bacteroides 
thetaiotaomicron 
(B. theta) 
Wild-type Provided by Martens Lab, University 
of Michigan 
Bacteroides 
thetaiotaomicron 
Δtdk 
Δtdk Used to produce genome mutations 
or deletions in B. theta through FUdR 
selection.  
Provided by Martens Lab, University 
of Michigan 
ΔBT2264 ΔBT2264SusC  B. theta with knockout of BT2264 
SusC homologue  
FLAG-BT2263 FLAG-tagged BT2263SusD B. theta with FLAG-tag added to the 
CT of BT2263 SusD homologue  
CT-HisBT1762 His-tagged BT1762SusD B. theta with Hisx6-tag added to the CT 
of BT1762 SusD homologue 
ΔBT1762SusD ΔBT1762SusD B. theta with knockout of BT1762 
SusD homologue 
Provided by Justin Sonnenburg, 
Stanford University (Cell 2010)  
W103A-BT1762 W103A of BT1762SusD B. theta with single base mutation of 
BT1762SusD tryptophan 103 to alanine 
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ΔHinge-BT1763 ΔHinge of BT1763SusC B. theta deletion of hinge loop L7 of 
BT1763SusC replaced with one glycine 
residue 
ΔDUF-BT1763 ΔDUF4480 of BT1763SusC B. theta with deletion of DUF4480 of 
BT1763SusC 
CT-HisBT1762/ 
ΔDUF-BT1763 
His-tagged BT1762SusD 
ΔDUF4480 of BT1763SusC 
B. theta with Hisx6-tagged CT of 
BT1762SusD and deletion of DUF4480 
of BT1763SusC 
Table 2.1 Bacterial strains and mutants 
Mutants in bold were produced during this study. C-terminal (CT) and N-terminal (NT) have been 
abbreviated.  
 
 
2.2. Vectors 
Vectors used in this study are listed in Table 2.2. 
Plasmid Size (kbp) Supplier Features 
pET28a 5.4 Novagen Kanr, T7 promoter, lac operator, 
laciq, multiple cloning site with 
integrated NT and CT Hisx6-tag  
pRSETA 2.9 Invitrogen Ampr, NT Hisx6-tag 
pET32b 5.9 Novagen Ampr, NT His-tag, Trx-tag, rEK 
cleavage site 
pET9 4.3 Susan Buchanan Kanr, PelB signal sequence, TEV 
protease-cleavable Hisx10-tag 
pB22 6.0 Van den Berg Lab plasmid 
(Guzman et al., 1995) 
Ampr, YtfM signal sequence, TEV 
protease-cleavable Hisx7-tag 
pExchange-tdk 4.2 Nicole Koropatkin (Koropatkin 
et al. 2008) 
Ampr 
Table 2.2 Vectors 
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2.3. Bacterial Growth Conditions 
2.3.1. Growth Media Composition 
All media compositions are outlined below (Table 2.3). Rich media were used when high cell 
density was required such as for recombinant protein expression. Minimal media for B. theta was 
used with 0.5 % (w/v) carbon source required to upregulate the PUL or protein of interest.  
 
Medium Components (per litre) Description/Method 
Luria-Bertani (LB) 25 g LB granules as supplied 
(Sigma-Aldrich) 
Rich media for E. coli 
Dissolved in H2O and pH adjusted to 7.2 
with NaOH. Autoclaved before use.  
LeMasters-
Richards (LR)  
24 g KH2PO4 
1 g NaOH 
4 g glucose 
10 ml LR salts (1.67.5 g/l (NH4)2SO4, 
30 g/l MgSO4.H2O, 300 mg/l 
FeSO4.7H2O, 1 ml/l conc H2SO4) 
Minimal media for producing Seleno-
methionine substituted protein by 
inhibition of the methionine 
biosynthesis pathway in E.coli 
Salts and media autoclaved separately. 
Glucose and salts added immediately 
before inoculation.    
Tryptone Yeast 
Extract Glucose 
(TYG) 
10 g Tryptone 
5 g Yeast Extract 
2 g Glucose 
0.5 g Cysteine, free base 
100 ml 1 M KPO4 pH 7.2 
40 ml TYG Salt Solution (MgSO4 
0.5 g/l, NaHCO3 10 g/l, NaCl 2 g/l) 
4 ml 0.25 mg/ml Resazurin 
1 ml 0.4 mg/ml FeSO4 
1 ml 1 mg/ml Vitamin K 
1 ml 0.8 % CaCl2 
Rich media for B. theta 
Components dissolved in H2O before 
autoclaving. His-heme* was added 
immediately before inoculation (1 μl 
per 1 ml of media) 
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Minimal Media 
(MM) 
1 g NH4SO4 
1 g Na2CO3 
0.5 g Cysteine, free base 
100 ml 1 M KPO4 pH 7.2 
50 ml MM Salt Solution (NaCl 
18 g/l, CaCl2 0.53 g/l, MgCl2 0.4 
g/l, MnCl2 0.2 g/l, CoCl2 0.2 g/l) 
10 ml 0.4 mg/ml FeSO4 
4 ml 0.25 mg/ml Resazurin 
1 ml 1 mg/ml Vitamin K 
0.5 ml 0.01 mg/ml Vitamin B12 
Minimal media for B. theta 
Prepared as with TYG.  
His-heme* was added immediately 
before inoculation (1 μl per 1 ml of 
media) 
 
Required carbon source added 
immediately before inoculation to final 
concentration of 0.5 % (w/v)  
Brain Heart 
Infusion (BHI) 
37.5 g BHI powder, as supplied 
(Sigma-Aldrich) 
Rich media for B. theta 
His-heme* was added immediately 
before inoculation (1 μl per 1 ml of 
media) 
*His-heme 1.2 g Hematin 
1 l. 0.42 g/l Histidine HCL pH 8 
Added to all B. theta media (1 μl per 1 
ml) after sterilisation 
Hematin dissolved in Histidine HCL 
solution by shaking at 37 °C for several 
hours 
Table 2.3 Composition of bacterial growth media  
 
2.3.2. E. coli growth Conditions 
E. coli strains (Table 2.1) were grown at 37 °C in the required sterile media (Table 2.3) with 
the appropriate antibiotic. A rotary shaker at 150-180 rpm was used to aerate the cells during the 
growth. For growth on a solid medium plates were produced by adding 2 % (w/v) Bacteriological 
agar (No. 1) (Oxoid) to the required media, autoclaving and allowing to cool. The required antibiotic 
was added immediately before pouring approximately 20 ml per plate into plastic Petri-dishes 
(Thermo Fisher Scientific). Plates were incubated with lid side down.  
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2.3.3. Bacteroides Growth Conditions 
B. theta was grown in either Tryptone Yeast Extract Glucose (TYG) rich media or Minimal 
media (MM) at 37 °C under anaerobic conditions in a cabinet (Don Whitely Scientific). Brain heart 
infusion (BHI) with His-heme and 2 % (w/v) agar was used to produce plates for B. theta growth. 
Plates were incubated with lid side down in the anaerobic cabinet.  
2.3.4. Selective Media 
Antibiotics were used within growth media to select for bacteria containing the desired 
plasmid. Stock solutions were produced and diluted 1:1000 into media (Table 2.4).  
Antibiotic Stock Concentration 
(mg/ml) 
Working Concentration 
(µg/ml) 
Storage 
Kanamycin 100 100 -20°C for 1 month 
Ampicillin 50 50 -20°C for 1 month 
Gentamycin 0.2 0.2 Freshly prepared  
Erythromycin 0.025 0.025 Freshly prepared 
Table 2.4 Antibiotic stocks  
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2.4. Basic Lab Methods 
2.4.1. Storage of DNA and Bacteria 
All DNA was stored in elution buffer (EB – 10 mM Tris-HCl buffer pH8.5) at -20 °C.  Bacterial 
colonies (E. coli or B. theta) on agar plates were stored at 4 °C for up to two weeks. For long term 
storage, bacteria in liquid media was mixed 1:1 with 50 % glycerol and stored at -80 °C. 
2.4.2. Sterilisation 
Solutions, media and glassware were sterilised by autoclaving at 121 °C under 32 lb/inch2 of 
pressure for 20 minutes using either an Astell Hearson 2000 Series Autoclave or a Prestige® Medical 
Series 2100 Clinical Autoclave. Small volumes of buffer or substrate were filter sterilised through 
0.22 µm sterile filter discs (Stupor Acrodisc 3.2 Gelman Sciences) using a suitable sterile syringe.  
2.4.3. Centrifugation 
Large-scale cultures of bacteria were harvested by centrifugation in 500 ml Nalgene bottles 
using a Beckman J2-21 centrifuge with JA-10 rotor. The maximum speed used was 8000 rpm (11305 
g). Small-scale cultures (1-10ml) were centrifuged at 5000 rpm (2516 x g) at 4 °C in a Hettich Mikro 
220R Refrigerated bench top centrifuge with fixed angle rotor. Eppendorf tubes (1.5 ml or 2 ml 
volume) were centrifuged using a Heraeus Pico 21 benchtop microcentrifuge at 14,000 rpm (21,100 
x g).  
Ultracentrifugation was carried out at up to 42,000 rpm (204526 x g) using a Beckman L8 – 80 
Ultracentrifuge and a 45 Ti rotor with 70 ml polycarbonate bottles (Beckman Coulter).  
2.4.4. Plating Bacteria 
Approximately 100 µl of bacterial suspension was transferred to an agar plate near a Bunsen 
burner flame. A metal spreader was immersed in 100 % ethanol and passed through the hottest 
(blue) part of the Bunsen flame. The spreader was allowed to cool for 20-30 seconds before 
spreading the bacterial suspension across the surface of the plate.  
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2.4.5. Transformation of Chemically Competent E. coli 
Chemically competent E. coli were produced with calcium chloride by Mr Carl Morland and 
stored at -80 °C (Cohen et al., 1972). A 100 µl aliquot of E. coli was thawed on ice before 1-5 µl of 
plasmid or ligation reaction was added. The mixture was incubated on ice for 30 minutes after which 
the cells were heat shocked at 42 °C for 1 minute before cooling on ice for a further 2 minutes. Cells 
were plated on LB agar containing an appropriate antibiotic to select for successful transformants. 
The plates were incubated lid side down at 37 °C for 16 hours.  
Ligated plasmids and products of site-directed mutagenesis require a recovery incubation 
after heat shocking. 500 µl of sterile LB was added and the cells were incubated at 37°C shaking for 1 
hour. The E. coli were harvested by centrifugation, 500 µl of media removed and the cells 
resuspended in the remaining media before plating.  
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2.5. DNA Methods 
2.5.1. Rapid, small-scale purification of plasmid DNA from E. coli 
The required plasmid was used to transform Top10 competent E. coli cells as outlined above. 
A single colony was picked to inoculate 5 ml LB with an appropriate antibiotic and incubated at 37 °C 
for 16 hours. The cultures were harvested by centrifugation at 2516 x g for 10 minutes. Plasmid 
purification was then carried out using a QIAspin Prep kit (QIAGEN) following the manufacturer’s 
protocol.  
2.5.2. B. theta genomic DNA extraction 
DNA was extracted from 5 ml cultures using GenElute Bacterial Genomic DNA kit (Sigma-
Aldrich) as per the manufacturer’s instructions.  
2.5.3. Quantification of DNA  
DNA concentration was determined using the NanoDrop 2000 benchtop spectrophotometer 
(Thermo Fisher Scientific). The machine was first blanked using 2 µl EB buffer or Sigma-Aldrich 
ultrapure water depending on the DNA solution. Absorbance for 2 µl of the DNA sample was 
measured at 260 nm. 
2.5.4. Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was used to amplify target DNA (Mullis et al., 1986). A 
thermostable DNA polymerase KOD (Novagen) was used to catalyse the synthesis of new 
complementary DNA strands based on a template (plasmid, genomic DNA or cell culture).  
Specific regions of DNA were targeted using primers 15-30 bases in length with a melting 
temperature (Tm) of >45°C (calculated using OligoCalc Table 2.16). Primers were designed to end in G 
or C bases, when possible, to aid annealing and thus increase efficiency of the reaction. If digestion 
of the DNA was required the specific target sequence for the endonuclease was included at the 5’-
end of the primer. For sequence and ligation independent cloning (SLIC) each primer was extended 
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by 15-18 bp homologous to the ends produced by digestion of the vector to allow for recombination. 
Primers were synthesised by MWG-Eurofins and received lyophilised. Primers were resuspended in 
PCR grade water to a working concentration of 100 pmol/µl. 
2.5.4.1. Standard PCR 
PCR reaction mixtures were prepared on ice as outlined in Table 2.5 using the KOD DNA 
polymerase kit (Novagen).  
Reagent Volume per reaction Amount per reaction 
KOD Buffer (10 x) 5 µl 1 x 
dNTPs (2 mM each) 5 µl 0.2 mM each 
MgSO4 (25 mM) 5 µl 2.5 mM 
Forward Primer (100 µM) 5 µl 10 µM 
Reverse Primer (100 µM) 5 µl 10 µM 
Template DNA  1 µl 50-200 ng 
KOD DNA polymerase (1 U/µl) 0.5 µl 0.5 U 
PCR grade H2O Up to total volume 50 µl - 
Table 2.5 PCR reaction mixture 
The standard thermocycler program for routine PCR is explained below in Table 2.6. 
Temperature (°C) Time Function 
 95 1 min Initial denaturing 
35 cycles 
 95 30 s Denaturing 
55 30 s Annealing 
68 1 min per kbp Extension 
 68 10 mins Final extension 
Table 2.6 Standard PCR program 
 
After each PCR a sample was analysed for product by gel electrophoresis. Low yield or no PCR 
product of the correct size was improved by altering the parameters of the reaction such as 
annealing temperature, extension time or MgSO4 concentration (1-5 µM). Dimethyl sulfoxide 
(DMSO) was also added to a final concentration of 5 to 10 % for some reactions.  
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2.5.4.2. Site-Directed Mutagenesis 
Single amino acid mutants were produced using site-directed mutagenesis (SDM). The 
double-stranded recombinant plasmid encoding the wild-type (WT) protein was mutated using two 
synthetic primers including the desired mutation and 12 bp in each direction complementary to the 
DNA template. The PCR reaction was prepared as above for routine PCR (Table 2.5) and the 
thermocycler program in Table 2.7 was used.  
Temperature (°C) Time Function 
 95 1 min Initial denaturing 
20 cycles 
 95 30 s Denaturing 
55 30 s Annealing 
68 1 min per kbp of plasmid Extension 
 68 10 mins Final extension 
Table 2.7 Standard PCR program for SDM 
 
The PCR reaction was purified as above and eluted in 30 µl EB buffer before 1 µl of DpnI 
(Thermo Fisher Scientific 10 U/µl) and 3 µl Tango Buffer were added. DpnI digests the methylated 
template DNA, leaving the unmethylated PCR product intact. The digestion reaction was incubated 
at 37 °C for 2 hours before 5 µl was used to directly transform E. coli cells.   
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2.5.4.3. Sewing PCR 
PCR overlap extensions or ‘sewing’ PCR was used to produce plasmids for homologous 
recombination to mutate the genome of B. theta. This method was used to remove segments of 
DNA (knockouts), mutate certain residues or to add extra amino acids such as a His-tag. A 
pExchange-tdk plasmid was required encoding the required mutation and a region of DNA 
homologous to the B. theta genome at least 1000 bp upstream and downstream of the mutation site 
(Figure 2.1A). These adjoining regions are referred to as flank 1 (upstream) and flank 2 
(downstream).  
Four primers were required to construct the mutated DNA fragment, two outside 
amplification primers and two internal mutation ‘sewing’ primers (Figure 2.1A). The outside 
amplification primers (1 and 4) were designed as for standard PCR with the required restriction sites. 
The internal primers (2 and 3) were homologous to the genome and the required mutation. For 
producing knockouts, the mutation extension of the primer was complementary to 20 bp of the 
opposite flank.  
The first step was creation of the two flanks with the mutation extension (Figure 2.1A). Two 
separate reactions were set up with primers 1 and 2 (Flank 1) alongside primer 3 and 4 (Flank 2) 
using routine PCR conditions. The second step links the flanks together at the complementary 
mutation site (Figure 2.1B). To obtain the 2000 bp final product the flanks were used in equal 
concentrations to avoid preferential amplification of one flank above the other. The first 10 PCR 
cycles were without primers to allow the flanks to act as template and primer to each other although 
this was not always required. The outside primers (1 and 4) were then added to amplify the sewn 
DNA fragment (Figure 2.1C). The final hybrid PCR product was purified and inserted into pExchange-
tdk vector using a ligation reaction (2.59) or Sequence and Ligation Independent Cloning (2.5.10). 
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Figure 2.1 Sewing PCR used to produce mutated gene fragments 
A: Two 1000 bp flanks upstream and downstream of the mutation site were amplified during 
individual PCR reactions. The outside half of primer 2 and 3 were homologous to the desired 
mutation. B: The resulting flanks become ‘sewn’ together by the complementary mutation 
sequence and are amplified by the outside primers (1 and 4) during a further PCR reaction. C: The 
final product consists of the central mutation and 1000 bp flanking regions.  
 
2.5.4.4. Agarose Gel Electrophoresis 
Size of linear DNA samples was determined using gel electrophoresis. A 1 % (w/v) agarose 
solution was prepared by mixing 500 mg of agarose (Sigma-Aldrich) in 50 ml 1 x TBE buffer (89 mM 
Tris Base, 89 mM Boric Acid, 2 mM EDTA). The agarose was dissolved completely by boiling, then 
allowed to cool (<50 °C) before 0.5 µg/ml ethidium bromide was added while the solution was still 
molten. The gel was poured into a mini gel system mould (Applied Biosystems) with a comb to 
produce wells for DNA loading. The gel was allowed to set at room temperature for a minimum of 30 
minutes before being submerged in 1 x TBE buffer.  
DNA samples were mixed with the appropriate volume of 10 x loading dye (0.25 % 
Bromophenol blue, 50 % glycerol, 10 x TBE) and loaded into the wells of the gel. DNA standards 
(Hyperladder I, Bioline) were run with the samples to allow estimation of DNA size by comparison. 
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Migration rate is inversely proportional to the log10 of the size of the fragment. The gels were run at 
70 V for 45 – 60 minutes (LKB Bromma 2197 Power Supply).  
2.5.5. Visualisation and Photography of Agarose Gels 
Following electrophoresis the gels were visualised using a Bio-Rad Gel Doc EZ Imager (Image 
Lab/ PC Windows software). Photographs were printed using a linked Mitubishi Video Copy 
Processor (Model P68B) with Mitsubishi thermal paper. 
2.5.6. Restriction Digest of DNA 
When available, 1000 ng of DNA was used per digest and the reaction carried out in a sterile 
1.5 ml Eppendorf. The required DNA (in EB buffer) was mixed with the appropriate volume of 10 x 
concentrated reaction buffer. The buffer was selected to optimise conditions for the specific 
endonuclease enzymes used in the reaction (Thermo Fisher Scientific). 0.5 – 1 µl of enzyme was 
added and the final volume was made up to 40 µl with Ultra-pure water (Sigma-Aldrich). The 
reaction mixture was incubated at 37 °C in a water bath for 1 hour then the DNA was purified 
(outlined below) to remove the enzymes and buffer.  
2.5.7. Purification of Vector DNA (Gel extraction) 
Following linearization of vector DNA using endonucleases, the sample was run on a 1 % 
(w/v) high purity Seachem Gold Agarose gel. Electrophoresis was carried out as described above. The 
band required was excised from the gel with a scalpel over a UV transilluminator. DNA was then 
extracted from the gel slice using a QIAquick Gel Extraction kit (QIAGEN) as per the maufacturer’s 
protocol.  
2.5.8. Purification of inserts and PCR products 
Digested DNA inserts for ligation and all PCR products were purified using the QIAquick PCR 
purification kit (QIAGEN) by following the manufacturer’s instructions.  
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2.5.9. Ligation of Insert and Vector DNA 
Vector and insert DNA digested with compatible endonucleases were mixed with an insert 
to vector molar ratio of 3:1. In each reaction 20 ng of vector DNA was used and the required amount 
of insert DNA was calculated using Equation 1. 
 
3 x 
 
Size of insert (bp) 
  
x amount of vector (ng) 
Size of vector (bp) 
 
Equation 1 - Calculating molar ratio of insert to vector DNA 
Ligation reactions using reagents from the Rapid DNA Ligation kit (Thermo Fisher Scientific) 
were mixed as outlined in Table 2.8 in 200 µl PCR tubes.  
Component Amount per reaction 
Vector DNA (digested) 20 ng total DNA 
Insert DNA (digested) Calculated using Equation 1 
5 x Ligation Buffer  4 µl 
T4 DNA Ligase 1 µl 
Sterile H2O Up to total 20 µl 
Table 2.8 Ligation reaction mixture 
 
The ligation reaction was incubated at room temperature for 30 minutes before 5 µl was 
used to directly transform chemically competent E. coli cells.  
2.5.10. Sequence and Ligation Independent Cloning  
An alternative method to using ligase is Sequence and Ligation Independent Cloning (SLIC) 
which uses T4 DNA polymerase (Jeong et al., 2012). This protocol was adapted from the method 
outlined in Jeong et al. 2012. Primers for amplification of the required gene were designed with 15 
bp extensions homologous to the ends produced by digestion of the vector. The insert with the 15 
bp extensions was generated via standard PCR. Only the vector was digested by endonuclease 
enzymes and purified as described above. The insert and vector were mixed together in 1:1, 2:1 or 
3:1 ratios with DNA amounts calculated using Equation 1. The SLIC reaction was prepared on ice as 
shown in Table 2.9. 
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Component Amount per reaction 
Vector DNA (digested) 100 ng 
Insert DNA Calculated using Equation 1 
BSA  1 µl 
NEB Buffer 2 1 µl 
T4 DNA polymerase 0.2 µl 
Sterile H2O Up to total 10 µl 
Table 2.9 Ligation Independent Cloning reaction mixture 
 
The SLIC mixture was incubated at room temperature for 2 minutes 30 seconds before 
transferring to ice for 10 minutes. 5 µl of the reaction was used to transform chemically competent 
E. coli by heat shock. 
 
2.5.11. Automated DNA sequencing 
DNA sequencing was conducted using the Value Read service provided by MWG-Eurofins. 
Pre-ordered labels provided by the company were applied to 1.5 ml Eppendorf tubes. For each 
sample, two tubes containing 50-100 ng of DNA (plasmid or PCR product) were sent for sequencing. 
Each clone or DNA fragment was sequenced in both the forward and reverse direction.  
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2.6. Microbiology 
2.6.1. Mutagenesis of the Bacteroides thetaiotaomicron genome 
A modified pExchange-tdk plasmid was produced containing the mutation and two flanking 
1000 bp regions (2.5.4.3.). The plasmid was transformed into S17 λ pir E. coli cells referred to as the 
‘donor’ strain, with B. theta Δtdk the ‘recipient’ strain (Koropatkin et al., 2008). The donor and 
recipient strains were cultured overnight to similar optical densities in 5 ml LB and TYG media 
respectively (Figure 2.2A). Cells were harvested by centrifugation and equal sized pellets were 
resuspended in 1 ml TYG (Figure 2.2B). The cells were plated evenly on BHI-heme agar without 
antibiotic and incubated aerobically for 24 hours. Due to the large volume of liquid the plates were 
incubated lid side up. A lawn of E. coli grew first creating an anaerobic environment underneath 
which allowed B. theta to grow, providing the necessary conditions for conjugation between donor 
and recipient (Figure 2.2B).  
The conjugation plates were scraped and the cells resuspended in 5 ml TYG (Figure 2.2C).  
100 µl of this solution and two 10-fold serial dilutions (1:10 and 1:100) were plated onto BHI-heme 
agar plates containing gentamycin (200 µg/ml) and erythromycin (25 µg/ml). The antibiotics select 
for the recipient strain and pExchange-tdk therefore colonies represent cells which have undergone 
single recombination of the plasmid with the genomic DNA via one of the flanks (Figure 2.2G). The 
plates were incubated anaerobically for up to 3 days, then 10 colonies were restreaked onto fresh 
BHI-heme plates with gentamycin and erythromycin to minimise contamination by WT B. theta 
(Figure 2.2C). 10 colonies were picked and cultured overnight in TYG (Figure 2.2D).  
The cells were pooled and 100 µl plated alongside two 10-fold serial dilutions (1:10 and 
1:100) onto BHI-heme agar containing FUdR (200 µg/ml) and incubated for up to 3 days (Figure 
2.2E). FUdR is toxic to strains which synthesise thymidine; the recipient B. theta Δtdk cannot 
produce thymidine but the knockout gene is complemented by the pExchange-tdk plasmid. 
Therefore FUdR selects for the second recombination event involving the second flank which 
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eliminates the pExchange tdk sequence from the genome (Figure 2.2G). The FUdR resistant colonies 
were restreaked onto fresh BHI-heme agar containing FUdR to reduce contamination with WT B. 
theta cells (Figure 2.2E).  
10 colonies from the second FUdR plate were cultured overnight in 5 ml TYG to allow 
extraction of genomic DNA (gDNA) and creation of glycerol stocks (Figure 2.2F). The isolated gDNA 
was screened for successful mutations using diagnostic PCR with the outside primers used to create 
the plasmid insert (primer 1 and 4 Figure 2.1). Deletions can be detected using agarose gel 
electrophoresis to compare the PCR product size produced from WT gDNA with the possible 
mutants. Genomic insertions such as the addition of tag sequences were detected using a specific 
primer homologous to the mutation therefore PCR will produce no product from WT gDNA. Strains 
which appeared to be correct after screening were sequenced to check the correct mutation had 
taken place and was in frame.        
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Figure 2.2 Generating mutant strains of Bacteroides thetaiotaomicron 
A: The donor and recipient strains were cultured overnight in 5 ml LB and TYG media respectively.  
B: Equal size cell pellets were harvested by centrifugation, resuspended and combined in 5 ml TYG. The 
cells were plated onto BHI-heme agar plates containing no antibiotic (peach) and incubated for 24 hours. 
C: The conjugation plates were scraped and the cells resuspended in 5 ml TYG. This was plated on BHI-
heme plates containing gentamycin (200 µg/ml) and erythromycin (25 µg/ml) (lilac). Resistant colonies 
were re-streaked on fresh plates to minimise WT contamination. D: 10 colonies were picked and grown 
overnight in TYG. These strains have undergone the first recombination event (G) E: The cultures were 
pooled and plated onto BHI containing FUdR (200 µg/ml) to select for the second recombination event 
(cyan). As before, colonies were re-streaked. F: 10 colonies were picked and cultured overnight in TYG. 
Glycerol stocks were prepared and DNA was extracted for analysis. G: A schematic diagram of the 
recombination. pExchange-tdk enters the genome by recombination with one flanking region (blue) in 
the first recombination event. The second recombination event involved the second flank (green) 
eliminating pExchange-tdk from the genome.      
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2.6.2. CFU growth curves of B. theta 
As outlined above (2.6.1.) pExchange-tdk was used to add a 4xAla linker and FLAG-tag 
(DYDDDDK) to the C-terminus of BT2263SusD in WT B. theta. The resulting mutant strain was grown in 
TYG rich media and minimal media containing 0.5% fructose anaerobically at 37 °C. 500 μl samples 
were collected over 24 hours and serial dilutions were plated in duplicate on BHI-heme agar. The 
dilution plates were incubated at 37 °C under anaerobic conditions for 3 days then the colonies were 
counted to calculate colony forming units (CFU) for each sample. The 500 μl samples of cells were 
harvested by centrifugation, resuspended in 100 μl of sterile 1 x PBS (Oxoid) and stored at -20 °C 
until required for Western blotting (2.1.2.1). The whole cells were diluted to relative CFU using 
Bugbuster detergent (100 μl per 2 x 109 cells). The samples were incubated at room temperature for 
20 minutes, centrifuged and the supernatant collected (stored at 4 °C).  
2.6.3. Automated monitoring of B. theta growth curves 
An Epoch microplate spectrometer (Biotek Instruments Ltd.) was used in conjunction with a 
96-well Costar culture plate (Sigma-Aldrich) inside an anaerobic chamber at 37 °C (Don Whitely 
Scientific). 200 µl cultures were used and each condition was prepared in triplicate to be averaged. 
Media without bacterial inoculum was always used as a control. The plate reader measured and 
recorded the optical density (at 600 nm) of each well at 15 minute intervals. Data was manipulated 
in Gen5 2.05 software and later plotted using Prism 6.0 (GraphPad).  
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2.7. Recombinant Protein Expression and Purification 
Soluble proteins were expressed recombinantly in E. coli via expression plasmids (Table 2.2).  
2.7.1. Protein expression in E. coli 
Plasmids encoding the required protein were transformed (2.4.5) into the appropriate E. coli 
strain. A single colony was used to inoculate 5 ml LB broth, with the suitable antibiotic, and 
incubated with shaking at 37 °C for 16 hours. 2 L baffled flasks containing 1 L sterile LB and the 
required antibiotic were inoculated with 1 ml of the overnight culture. The flasks were incubated 
shaking at 37 °C until the culture reached an OD600nm of 0.6 – 0.8.  The cells were induced using the 
required reagent for the plasmid and incubated at 16 or 18°C overnight. The specific expression 
conditions for the proteins used in this study are listed in Table 2.10. Cells were harvested by 
centrifugation for 10 minutes at 4412 x g using a Beckman J2-21 centrifuge with JA-10 rotor.  
Protein Plasmid Antibiotic E. coli Induction Temp. (°C) 
BT2262LP pET9 Kan BL21 0.2 mM IPTG 18 
BT2263SusD pET9 Kan BL21 0.2 mM IPTG 18 
BT2263SusD pET28a Kan BL21 1 mM IPTG 16 
BT1760GH32 pET32b Amp BL21 1 mM IPTG 16 
BT1760GH32 pET28a Kan BL21 1 mM IPTG 16 
BT1761SGBP pET28a Kan BL21 1 mM IPTG 16 
BT1761SGBP pB22 Amp TUNER 100 mg/l 
arabinose 
16 
BT1762SusD pRSETA Amp BL21 1 mM IPTG 16 
Table 2.10 Induction and growth conditions for recombinant protein expression  
LP is a lipoprotein, SusD is a homologue of SusD, GH32 is a glycoside hydrolase enzyme and SGBP 
is a surface glycan binding protein 
  
 
45 
 
2.7.2. Seleno-methionine incorporation 
This method for expressing seleno-methionine (SeMet) substituted protein is based on the 
inhibition of the methionine biosynthesis pathway protocol for E. coli (Van Duyne et al., 1993). 
Expression plasmids encoding the desired protein were transformed into an appropriate E. coli 
strain. The appropriate antibiotic was added to all growth media to retain the plasmid. The 
transformed cells were used to inoculate 5 ml LB and the culture was incubated shaking at 37 °C for 
6 – 8 hours. 1 ml of the initial culture was used to inoculate 100 ml of LeMasters-Richards (LR) media 
(Table 2.3) and grown overnight at 37 °C. 1 litre of LR media (in 2 litre baffled flasks) was inoculated 
with 10 ml of the overnight culture and incubated at 37 °C for approximately 8 hours to OD600nm of 
0.6 – 1.0. Amino acids (Lys/Phe/Thr 100 mg/L each and Leu/Ile/Val 50 mg/L each) and SeMet (60 
mg/L) were added to the culture and incubated for a further 30 minutes. The cells were then 
induced and incubated overnight as above (Table 2.10).  
2.7.3. Immobilised Metal Affinity Chromatography (IMAC) 
All soluble proteins used in this study were expressed with a His-tag comprising of at least six 
histidine residues. The proteins were purified by immobilised metal affinity chromatography (IMAC) 
whereby the histidine residues interact with an electropositive transition metal (e.g. nickel or cobalt) 
immobilised in a column. Imidazole disrupts the interaction by competitively binding the metal ions 
which forces the His-tagged protein to be eluted from the column.   
Harvested cells were resuspended in TALON buffer (20 mM Tris, 300 mM NaCl, pH 8) which 
could be stored at -20 °C for up to 3 months if required. The cell suspension was transferred to a 50 
ml centrifuge tube (Nalgene) and sonicated on ice for 2 minutes using a B. Braun Labsonic U 
sonicator set at low intensity (~42 watts and 0.5 second cycling). The sample was centrifuged for 30 
minutes at 27143 x g and the supernatant, refered to as the cell free extract (CFE) was collected. The 
CFE was passed through a 0.45 µM syringe filter before loading onto the column.  
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Gravity-flow columns were prepared with 4 ml TALON resin (Clontech Laboratories Inc.) 
containing cobalt ions and equilibrated in 40 ml TALON buffer. The CFE was loaded onto the column 
and the flow through liquid was collected. The column was washed with 2 x 20 ml TALON buffer. The 
protein was eluted in two fractions; 10 ml TALON buffer with 5 mM imidazole followed by 10 ml 
TALON buffer with 100 mM Imidazole. SDS-PAGE was used to analyse each stage of the protein 
purification.  
2.7.4. SDS-PAGE 
Protein was visualised using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) to determine approximate protein size, quantity and purity (Laemmli, 1970). 12.5 % 
polyacrylamide gels (Acrylogel 3; BDH Electran) were routinely used with AE-6450 apparatus from 
ATTO Corporation (Genetic Research Instruments) consisting of two 12 cm x 10 cm glass plates 
sealed with a rubber gasket.  
All buffers required for preparation and running of SDS-PAGE gels are outlined in Table 2.11. 
The resolving gel was pipetted between the plates leaving 2 cm from the top which was covered in 
water. The gel was allowed to polymerise before the water was removed. The liquid stacking 
solution was poured on top of the resolving gel and a comb was inserted to form loading wells. 
Following polymerisation of the second gel layer, the comb and gasket were removed and the gel 
affixed in the gel tank with running buffer. Loading dye was added to protein samples at a ratio of 
1:2 and samples were boiled for 5 minutes when required. Molecular weight (MW) protein 
standards were loaded into a well alongside the protein samples and a current of 35 A (per gel) was 
applied. Gels were run for 30 – 45 minutes or until the dye front (from the loading buffer) had 
reached the end of the gel.    
After electrophoresis, the gel was stained in InstantBlue stain (Expedeon) for 15 – 30 
minutes to reveal protein bands. The gel was destained overnight using distilled water and an orbital 
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shaker. Gels were then photographed using Bio-Rad Gel Doc EZ Imager (Image Lab/ PC Windows 
software).  
Component Reagent Concentration or 
Volume 
Resolving Gel (per 
gel) 
0.75 M Tris/HCl, pH 8.8 with 0.2 % SDS 
40 % Acrylamide (BDH Electran acrylamide, 3 % (w/v) 
bisacrylamide) 
d.d. H2O 
10 % (w/v) Ammonium persulphate 
TEMED 
2.35 ml 
1.45 ml  
 
0.875 ml 
22.5 µl 
7.5 µl  
Stacking Gel (per 
gel) 
0.25 M Tris/HCl, pH 6.8 with 0.2 % SDS 
40 % Acrylamide (BDH Electran acrylamide, 3 % (w/v) 
bisacrylamide) 
d.d. H2O 
10 % (w/v) Ammonium persulphate 
TEMED 
0.938 ml 
0.188 ml 
 
0.75ml 
15 µl 
5 µl 
Running Buffer (1 
litre) 
32 mM Tris / 190 mM glycine, pH 8.3 
SDS 
350 ml 
0.1 % (w/v) 
Loading Buffer (10 
ml) 
0.25M Tris/HCl, pH 8.8 
Glycerol 
SDS 
β-mercaptoethanol 
Bromophenol blue dye 
5 ml 
25 % (w/v) 
10 % (w/v) 
2.5 ml 
0.1 % (v/v) 
Table 2.11 Gel and buffer recipes for SDS-PAGE 
 
2.7.5. Removal of His-tag by TEV digest 
Recombinant GFP-TEV protease (pET28a) was expressed in BL21 E. coli cells. The soluble 
protein was purified by IMAC and size exclusion chromatography (SEC) before adding 50 % (w/v) 
glycerol, flash freezing aliquots in liquid nitrogen and storing at -80 °C.  
Following initial purification by IMAC, the N-terminal His-tag was removed from protein 
expressed via pET9 or pB22 vectors (Table 2.2). The protein sample was buffer exchanged (2.7.9)  
into TEV cleavage buffer (50 mM NaCl, 50 mM Tris pH 8, 0.5 mM EDTA, 0.5 mM TCEP). The total 
protein amount was calculated using A280nm (2.7.7) and TEV protease was added to a weight ratio of 
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1:10 (TEV:Protein). The reaction volume was adjusted to 10 ml with TEV cleavage buffer and the 
sample was incubated, rotating, at 20 °C for 16 – 20 hours.  
The sample was buffer exchanged into TALON buffer and a second IMAC purification (2.7.3.) 
was carried out. The purified protein, lacking a His-tag, was collected in the flow through and wash 
fractions of the purification. The TEV protease and cleaved His-tag remain bound to the column.  
 
2.7.6. Size exclusion chromatography (SEC) 
Protein samples were concentrated to <5 ml for further purification by size exclusion 
chromatography (SEC). A HiLoad 16/60 Superdex 200pg 120 ml column (GE Healthcare) gel filtration 
column was used with the ÄKTA pure fast protein liquid chromatography system (GE Healthcare). 
The column was pre-equilibrated in the required buffer (typically 10 mM HEPES pH 7.5, 100 mM 
NaCl) before loading the concentrated sample. The proteins were separated on the column at a flow 
rate of 1.2 ml/min and 2 ml fractions were collected. Fractions were analysed using SDS-PAGE.  
 
2.7.7. Determination of Protein Concentration 
Protein concentration was determined using NanoDrop 2000 benchtop spectrophotometer 
(Thermo Fisher Scientific). 2 µl of purified protein sample loaded onto the detector and A280-320nm was 
analysed. The protein concentration was calculated using Equation 2. 
A = ɛClD 
Equation 2 – Calculating molar concentration of a protein solution 
Where A = absorbance at 280 nm – absorbance at 320 nm, ɛ = molar extinction 
coefficient, C = molar concentration of the sample, l = length of light path (cm),  
D = dilution factor  
 
The extinction coefficient for each protein was calculated by entering the specific amino acid 
sequence of the expressed protein into the ProtParam tool (Table 2.16). Alternatively, the 
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absorbance of a 0.1 % (1 g/l) solution of the specific protein (ɛ0.1%) was predicted using ProtParam 
and used to calculate protein concentration in mg/ml using A280nm and Equation 3.  
Protein concentration (mg/ml) = 
A  
ɛ0.1%  
Equation 3 – Calculating concentration of a protein solution in mg/ml 
Where A = absorbance at 280 nm, ɛ0.1% = 0.1% extinction coefficient.  
 
 
 
2.7.8. Centrifugal concentration of Proteins 
Protein solutions were concentrated as required using 20 ml Vivaspin (Sartorius) or 15 ml 
Amicon Ultra-15 (Merck) centrifugal concentrators with 30, 50 or 100 kDa molecular weight cut off 
filters as appropriate. Centrifugation was carried out using a Heraeus Megafuge 16R (Thermo Fisher 
Scientific) or an Eppendorf 5804R bench-top centrifuge at 4200 rpm (3215 x g) with swing out rotor 
at 10 °C.  
2.7.9. Buffer Exchange 
Soluble proteins in small volumes were buffer-exchanged using centrifugal concentrators as 
above. The sample was concentrated to <1 ml then diluted with the desired buffer up to 20 ml. The 
concentration and dilution was repeated to ensure complete buffer exchange.  
Larger volumes of buffer were exchanged using dialysis. Protein samples were contained 
within a section of dialysis tubing with a MW cut-off of 12 kDa and both ends sealed with clips. The 
tubing was submerged in 4 l of the appropriate buffer and stirred at 4°C overnight to allow buffer 
exchange.  
  
50 
 
2.8. Native Protein Expression and Purification from B. theta 
2.8.1. Protein expression in B. theta  
The required strain of B. theta from -80 °C stocks was used to directly inoculate 5 ml TYG rich 
media with added His-heme (Table 2.3). The culture was incubated at 37 °C overnight under 
anaerobic conditions (A35 Workstation anaerobic cabinet, Don Whitely Scientific). The desired 
media (TYG or MM, Table 2.3) for large scale growths was made and decanted into 500 ml DURAN 
glass bottles. The media was autoclaved and allowed to fully cool before use. 500 µl of His-heme was 
added to each bottle and 5 ml 50 % fructose if required (MM only). The media was then inoculated 
with 500 µl overnight culture and incubated at 37 °C under anaerobic conditions for 18 – 20 hours to 
OD600nm 1.5 – 2.0. Cells were harvested by centrifugation at 11305 x g for 30 minutes. Cell pellets 
were resuspended in TALON buffer and stored at -20 °C until processed for protein purification.  
2.8.2. Selenomethionine incorporation 
10 litres of wild type B. theta were grown in TYG medium as described above then harvested 
by centrifuging at 11305 g for 30 minutes. The cells were resuspended and used to inoculate 10 litres 
of MM containing 0.5 % (w/v) fructose. The cells were incubated at 37°C anaerobically for 30 
minutes before the addition of amino acids (Lys, Phe, Thr, Leu, Ile, Val) and selenomethionine, 
according to a protocol developed for SeMet incorporation in E. coli by inhibition of methionine 
biosynthesis (Van Duyne et al., 1993). The cells were incubated for a further 17 hours to a final 
OD600nm of 1.7 and harvested as described.   
2.8.3. Outer membrane purification 
Cells were thawed completely and lysed at a pressure of 23 kilopounds per square inch 
(KPSI) using a cell disrupter (Constant Systems). The cells were centrifuged a 42,000 rpm (204526 x 
g) for 1 hour to collect total membranes and the supernatant (CFE) was discarded. The pellets were 
resuspended using a glass homogoniser in 0.5 % (w/v) Sodium Lauroyl Sarcosine (sarkosyl), Table 
2.12. Sarkosyl selectively solubilises inner membrane (IM) proteins of gram negative bacteria (Filip et 
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al., 1973). The sample was incubated stirring at room temperature for 30 minutes and centrifuged at 
204526 x g for 30 minutes. The supernatant was discarded and the sarkosyl wash was repeated. The 
pellets were resuspended and homogenised in a suitable buffer with Lauryldimethylamine-N-oxide 
(LDAO) (Table 2.12) and incubated stirring at room temperature for 1 hour, or at 4 °C overnight. The 
sample was centrifuged at 204526 x g for 30 minutes and the supernatant containing solubulised 
outer membrane proteins (OMPs) was collected.  
 
2.8.4. Determination of total protein concentration 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) was used to determine the total 
solubilised protein. 10 µl of sample was added to 500 µl reagent A and 10 µl reagent B. Protein 
standards were set up containing 0 µg, 2 µg, 5 µg and 10 µg of BSA with the equivalent reagents. All 
samples were mixed well by vortexing and incubated at 45 °C for 1 hour. The A562nm was taken for 
each sample using a BioSpectrometer (eppendorf). The BSA standards were used to produce a 
standard curve of absorbance at 562 nm against total protein (µg). The total protein in the 
membrane sample was then calculated using the equation for the standard curve.  
  
Buffer Function Recipe pH Detergent (w/v) 
Sarkosyl Buffer Solubilising inner membranes 20 mM HEPES 7.5 0.5 % Sarkosyl 
LDAO Buffer Solubilising OMPs for anion 
exchange 
10 mM HEPES/ 50 mM NaCl 7.5 1 % LDAO 
TALON-LDAO Buffer Solubilising OMPs for IMAC 20 mM Tris/ 300 mM NaCl 8 1.5 % LDAO 
Table 2.12 Buffers for solubilising OMPs from B. theta 
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2.8.5. Anion-exchange chromatography 
Anion-exchange (IEX) was used to separate B. theta OMPs for identification and was ultimately 
used for the purification of the BT2261-4 complex. To avoid overloading the column the cells were 
processed in batches of 2-3 litres. The solubilised total membrane sample was passed through a 0.45 
µm filter and loaded onto a Resource Q 6 ml anion exchange column using the ÄKTA pure system 
(GE healthcare). The proteins were separated with a salt gradient from 50 mM to 1 M in 20 column 
volumes (Table 2.13). Peak fractions were analysed using SDS-PAGE 
2.8.6. Immobilised Metal Affinity Chromatography (IMAC) 
BT1762-3 was purified using a C-terminal Hisx6-tag added to the genomic copy of BT1762SusD 
which allowed separation by IMAC. Gravity-flow columns were prepared with 10 ml TALON resin 
(Clontech Laboratories Inc.) containing cobalt ions and equilibrated in 100 ml TALON equilibration 
buffer (Table 2.14). The solubilised membrane sample in TALON-LDAO buffer was loaded slowly onto 
the column washed with 150 ml TALON wash buffer. The protein was eluted in 20 ml TALON buffer 
with 100 mM Imidazole. SDS-PAGE was used to analyse the IMAC samples.  
 
Buffer Function Recipe pH Detergent (w/v) 
IEX Buffer A Equilibration 10 mM HEPES/ 50 mM NaCl 8 0.06 % LDAO 
IEX Buffer B Elution 10 mM HEPES/ 1 M NaCl 8 0.06 % LDAO 
Table 2.13 Buffers used for anion-exchange chromatography of B. theta OMPs 
 
Buffer Function Recipe pH Detergent (w/v) 
TALON equilibration buffer Equilibration  20 mM Tris, 300 mM NaCl 8 0.2 % LDAO 
TALON wash buffer Washing the column 20 mM Tris, 300 mM NaCl 
5 mM Imidazole 
8 0.2 % LDAO 
TALON elution buffer Elution of bound OMPS  20 mM Tris, 300 mM NaCl 
100 mM Imidazole 
8 0.2 % LDAO 
Table 2.14 Buffers for solubilising OMPs from B. theta 
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2.8.7. Size exclusion chromatography (SEC) 
Membrane proteins from anion exchange or IMAC were further purified by size exclusion 
chromatography (SEC). A HiLoad 16/60 Superdex 200pg 120 ml gel filtration column (GE Healthcare) 
with the ÄKTA pure system (GE healthcare) was used. The column was first equilibrated in the 
required buffer with LDAO or n-Decyl-β-D-Maltopyranoside (DM) detergent (Table 2.15). The sample 
was concentrated to <5 ml and loaded onto the column. The proteins were eluted at 1.2 ml/min and 
3 ml fractions were collected. Peak samples of interest were analysed using SDS-PAGE. A second SEC 
run was used to buffer exchange the protein into a final buffer with 0.4 % tetraethylene glycol 
monooctyl ether detergent (C8E4, Table 2.15) for crystallisation.  
 
2.8.8. SDS-PAGE of B. theta OMPs 
Samples were prepared with loading buffer (NuPAGE LDS sample buffer (4 x), Thermo Fisher 
Scientific) and boiled for 5 minutes, if required. Membrane protein samples were generally analysed 
boiled and non-boiled as many OMPs are heat modifiable (Beher et al., 1980). A NuPAGE 4-12 % Bis-
Tris protein gel was inserted into the XCell SureLock Mini-Cell tank which was filled with 1 x NuPAGE 
MOPS SDS Running Buffer (Gel, tank and buffer - Thermo Fisher Scientific). Up to 15 µl of each 
sample was loaded onto the gel alongside 5 µl Novex Pre-stained Protein Standard (Thermo Fisher 
Scientific). Gels were run at 180 V for 75 – 90 minutes or until the dye front (from the loading buffer) 
had reached the end of the gel.  
Buffer Function Recipe pH Detergent (w/v) 
DM SEC Buffer Size exclusion column 10 mM HEPES/ 100 mM NaCl 7.5 0.12 % DM 
LDAO SEC Buffer Size exclusion column 10 mM HEPES/ 100 mM NaCl 7.5 0.05 % LDAO 
C8E4 Buffer Final protein buffer 10 mM HEPES/ 100 mM NaCl 7.5 0.4 %  C8E4 
Table 2.15 Size exclusion chromatography buffers for OMPs from B. theta 
54 
 
The gel was removed from the tank, the plates separated and the gel transferred to a 
staining tray. The gel was covered in water, microwaved for 1 minute, and incubated for 5 – 10 
minutes on an orbital shaker. The washing steps were repeated to ensure removal of SDS from the 
gel. Coomassie Blue stain (0.01 % Coomassie, 10% ethanol, 30mM HCl) was used to cover the gel and 
incubated for 1 hour. The stain was removed and the gel rinsed in water. The gel was then destained 
by incubating overnight in water. Gels were photographed using Bio-Rad Gel Doc EZ Imager (Image 
Lab/ PC Windows software). 
2.8.9. Native PAGE 
Samples were prepared with 0.5 % n-Dodecyl β-D-maltoside (DDM), 1 x NativePAGE sample 
buffer and NativePAGE G-250 Additive as per the manufacturer’s instructions (Thermo Fisher 
Scientific). NativePAGE 4-16% Bis-Tris Protein Gels were used with the NativePAGE Anode Buffer and 
NativePAGE Dark Blue Cathode Buffer which were prepared following the manufacturer’s protocol 
(Thermo Fisher Scientific). The samples were run at 180 V for 90 – 120 minutes using the XCell 
SureLock Mini-Cell tank (Thermo Fisher Scientific). 
The gel was transferred to a staining tray, covered with 100 ml Fix Solution (40 % Methanol, 
10 % Acetic Acid) and microwaved for 45 seconds. The gel was incubated on an orbital shaker for 15 
minutes before the Fix Solution was removed. 100 ml Destain Solution (8 % Acetic acid) was added 
to the tray and the gel was incubated overnight to remove the excess stain. Native gels were 
photographed using Bio-Rad Gel Doc EZ Imager (Image Lab/ PC Windows software).  
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2.9. Crystallography 
2.9.1. Protein crystallisation trials 
Membrane and soluble proteins for crystallisation were purified by IMAC or ion exchange 
chromatography followed by SEC (Sections 2.7 and 2.8). Proteins were concentrated (Section 2.7.8) 
to 10 – 20 mg/ml in buffer used for SEC. Protein crystallisation was performed using the sitting-drop 
vapour-diffusion method. Initial screens were set up using an automated Mosquito Crystal nanolitre 
dispensing robot (TTP Labtech) onto MRC 96-well crystallisation plates (Molecular Dimensions). 
Commercial crystallisation screens from Molecular Dimensions MemGold 1 and MemGold 2 were 
used for membrane proteins and complexes. For soluble proteins appropriate screens were selected 
from a wide range; Structure PACT, Morpheus and JCSG Plus (Molecular Dimensions), Index 
(Hampton Research), JCSG core (I to IV) Suite and AmSO4 Suite (QIAGEN). Solutions were dispensed 
200 nl + 200 nl and 200 nl + 150 nl of protein and crystallisation solution, respectively. The ratio of 
protein to crystallisation solution was varied when required. Crystallisation plates were incubated at 
20 °C.  
2.9.2. Optimising protein crystals 
Optimisation of initial crystal hits was generally carried out by hand using the hanging-drop 
vapour diffusion method with XRL or VDX 24-well hanging drop plates (Molecular Dimensions).  
Original screen conditions were replicated with varied precipitant concentrations. If this was 
unsuccessful, further optimisations were carried out modifying the concentration of the salt or pH of 
the buffer. Routinely 0.8 µl + 0.8 µl and 1.2 µl + 0.8 µl of proteins and crystallisation solutions, 
respectively, were dispensed.   
The exception to this method was the BT1760-3 crystals which could not be replicated by 
manual sitting or hanging drops. The Mosquito was used to dispense 400 nl + 400 nl and 400 nl + 300 
nl of protein and crystallisation solution, respectively, onto Intelli 48-3 sitting drop plates.  
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2.10. Structural Biology  
2.10.1. In-house screening of crystals for diffraction 
Crystals were harvested in suitably sized loops (Hampton) by Bert van den Berg, cryo-
protected in an appropriate buffer and flash frozen immediately in liquid nitrogen. Crystals were 
mounted on a copper anode Rigaku MSC microfocus generator and data collected at a 1.54 Å on a 
Raxis IV++ image plate detector. The diffraction images were indexed in MOSFLM. Crystals were 
ranked based on resolution and diffraction pattern with the most suitable crystals sent for data 
collection.  
2.10.2. Data Collection 
Datasets were collected on the most suitable beamline at Diamond Light Source (DLS, 
Didcot, Oxfordshire, UK) by Dr. Arnaud Baslé. 
2.10.3. Solving BT2263 SusD homologue by Molecular Replacement 
X-ray Detector Software (XDS) was used to determine the space group, index and scale 
BT2263 diffraction data (Kabsch, 2010). The data was used to a resolution of 1.9 Å. BT2259 SusD-like 
was used as the MR model (PDB ID: 4Q69 26 % identity to BT2263SusD). MR of the scaled data with 
the model was carried out in Phaser-MR within Phenix (Adams et al., 2010). One round of 
refinement was used, followed by Autobuild (Resolve and Buccaneer). The resulting model had Rwork 
0.243 and Rfree 0.270. Several rounds of building and editing the structure by hand in Coot followed 
by refinement in Phenix were used to complete the model (Adams et al., 2010). The final Rfree for the 
BT2263SusD structure was 0.198. 
2.10.4. Structures solved by Bert van den Berg 
The remaining structures presented in this study were solved by Bert van den Berg; Soluble 
BT2262 lipoprotein, BT2261-4 complex, BT1762-3 apo and BT1762-3 with ligand.  
  
57 
 
2.11. Bioinformatics 
Bioinformatics tools used in this study are listed in Table 2.16 below.  
Bioinformatic Tool Website Description 
Genetic and 
Proteomic 
tools 
BLAST https://blast.ncbi.nlm.nih.gov/Bla
st.cgi Hosted by the National 
Centre for Biotechnology 
Information (NCBI) 
Finds proteins with conserved 
regions (homologues). The 
query sequence is compared 
to a database of non-
redundant protein sequences. 
InterPro  https://www.ebi.ac.uk/interpro/  Prediction of protein domains 
based on the amino acid 
sequence 
Pfam 31.0 http://pfam.xfam.org/ 
 
Database of protein domains 
KEGG http://www.genome.jp/kegg/ 
 
Kyoto Encyclopedia of Genes 
and Genomes. Used to search 
for DNA/protein sequences 
and organisation of proteins 
within the genome. 
Prediction of 
signal 
peptides 
Signal P 4.1 
  
http://www.cbs.dtu.dk/services/S
ignalP/ Hosted by the Center for 
Biological Sequence Analysis  
Prediction of signal peptides 
in Gram-negative or Gram-
positive bacteria  
Protein 
Parameters 
ProtParam http://web.expasy.org/protpara
m/ From ExPASy Bioinformatics 
Resource Portal  
Calculates protein parameters 
(molecular weight, isoelectric 
point and extinction 
coefficient) based on protein 
sequence 
Primer Design 
OligoCalc http://biotools.nubic.northwester
n.edu/OligoCalc.html 
 
Calculates oligonucleotide 
parameters (melting temp, 
G/C content etc.) based on 
DNA sequence. 
WEBcutter 
2.0 
http://rna.lundberg.gu.se/cutter2
/  
Finds restriction enzyme sites 
within a DNA sequence 
Alignment 
tools 
Clustal 
Omega 
http://www.ebi.ac.uk/Tools/msa/
clustalo/ Hosted at the European 
Bioinformatics Institute (EBI) 
website 
Multiple alignment of amino 
acid sequences. 
Multalin  http://multalin.toulouse.inra.fr/
multalin/ 
Multiple alignment of amino 
acid or DNA sequences. 
Structures 
PDB https://www.rcsb.org/pdb/ 
 
Protein Data Bank. Database 
of protein structures  
Table 2.16 Bioinformatics tools 
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2.12. Biochemistry 
2.12.1. Western Blotting 
Samples were analysed alongside MagicMark XP Western Protein Standard (Thermo Fisher 
Scientific) using SDS-PAGE as described above (2.7.4.). Protein was then transferred to an Amersham 
Protran 0.45 Nitrocellulose membrane (GE Healthcare) using transfer buffer pre-cooled to 4 °C 
(Table 2.16) and the Mini Trans-Blot system (Bio-Rad). The transfer was carried out at 80 V for 90 
minutes. The buffer was kept cold during the transfer using a freezer block and a magnetic stirrer.  
The membrane was blocked for 1 hour at room temperature or overnight at 4 °C in blocking 
buffer (Table 2.17). The blot was then incubated with the required primary antibody in 10 ml 
antibody buffer for 1 hour. Anti-Flag antibody (F7425, Sigma-Aldrich) was used 1:2000 and the Anti-
Hisx6-Peroxidase (11965085001 ROCHE, Sigma-Aldrich) antibody was used 1:5000. The primary 
antibody was removed by washing three times for 5 minutes each with wash buffer (Table 2.17). 
FLAG western blots required a secondary antibody; Goat Anti-rabbit-HRP antibody (sc-2004, Santa 
cruz) 1:5000. The secondary antibody was diluted in the antibody buffer, the membrane was 
incubated for 1 hour and washed as before.  
The blot was developed using 500 µl each of the Clarity Western ECL reagents (Bio-rad). An 
image of the membrane was produced using ChemiDoc XRS+ System (Bio-Rad).  
Buffer Component Amount  Concentration 
Transfer Buffer 
(1 litre) 
Tris - HCl 
Glycine 
SDS 
Methanol 
Water 
3 g 
14.3 g 
0.5 g 
300 ml 
200 ml 
25 mM 
192 mM 
1.7 mM 
30 % 
- 
Blocking Buffer  
(10 ml) 
1 x PBS (Oxoid, 1 tablet per 100 ml) 
Milk powder 
Tween 20 
10 ml 
0.5 g  
50 µl 
- 
5 % 
0.5 % 
Antibody Buffer 
(10 ml) 
1 x PBS (Oxoid, 1 tablet per 100 ml) 
Milk powder 
10 ml 
0.5 g  
- 
5 % 
Wash Buffer 
(50 ml) 
1 x PBS (Oxoid, 1 tablet per 100 ml) 
Tween 20 
50 ml 
250 µl 
- 
0.5 % 
Table 2.17 Buffers required for Western Blotting  
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2.12.2. Isothermal Titration Calorimetry (ITC) 
Isothermal Titration Calorimetry (ITC) can determine the thermodynamic parameters driving 
macromolecular interactions by titrating ligand into protein. The experiment was carried out using a 
MicroCal VP-Isothermal Titration Calorimeter at 25 °C. The heat consumed or released in the 
reaction cell was measured in comparison to a reference cell at stable temperature. The cell and 
syringe were equilibrated by dialysis (Section 2.7.9) in 20 mM HEPES pH7.5 with the protein and 
ligand used in the identical buffer. The protein in the cell (40 – 60 µM) was equilibrated to 25 °C. The 
ligand (5 – 10 mM or 5 – 10 mg/ml) was titrated into the cell, from the syringe, in 28 aliquots of 10 
µl. Integrated heat effects were analysed by non-linear regression using a single site-binding model 
(MicroCal Origin v7) giving the association constant (Ka) and enthalpy of binding (ΔH).  
2.12.3. Thin Layer Chromatography (TLC) 
Thin Layer Chromatography (TLC) allows a mixture of oligosaccharides to be visualised. TLC 
plates (Silica gel 60, Sigma-Aldrich) were cut to size and 2 – 6 µl of samples were spotted onto plates 
1 cm from the bottom. The spots were dried and the plate placed into a tank containing 1 cm of 
running buffer (1-butanol, acetic acid and water at 2:1:1). The running buffer migrated to within 1 
cm of the top of the plate which was dried and replaced in the tank to migrate again. The plate was 
dried completely and submerged in developer solution (sulphuric acid, ethanol and water at 3:70:20 
with 1% orcinol) for 5 – 10 seconds. The plate was dried and incubated at 80 – 100 °C until 
sufficiently developed.  
2.12.4. Oligosaccharide Production and Purification 
Initial small-scale time course digests of levan were carried out and analysed by TLC to find 
the optimal parameters for a partial digest of the polysaccharide. The reaction was scaled up to 
produce sufficient oligosaccharides for purification.  
500 mg of levan (Erwinia herbicola, Sigma-Aldrich) was dissolved in 100 ml of PBS (Oxoid) by 
warming in a hot waterbath 60 – 80 °C. The solution was allowed to cool before 100 nM BT1760 
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endo-acting GH32 levanase was added and the reaction was incubated in a 37 °C waterbath for 20 
minutes. The reaction was heat inactivated by boiling for 20 min. The sample was incubated at -80 °C 
for 1 hour and freeze dried using a Christ Alpha 1-2 Freeze Drier at -60 °C. The resulting powder was 
then resuspended in 5 ml of H2O for purification. 
The partially digested levan products were separated by size exclusion chromatography 
using P2 Bio-gel (Bio-Rad) matrix packed in 2 Glass Econo-Columns (2.5 cm × 80.0 cm) with a flow 
adaptor (Bio-Rad). The column was pre-equilibrated in 50 mM Acetic acid and the digest was loaded 
directly onto the column bed. The oligosaccharides were separated and eluted from the column at 
0.25 ml/min in using a peristaltic pump (LKB Bromma 2132 microperpex). The 2 ml fractions were 
collected continuously for 48 hours using a Bio-Rad model 2110 fraction collector. A 2 μl aliquot of 
every fifth fraction was analysed by TLC identifying fractions of interest. Freeze drying was used to 
remove the acetic acid from the fractions.  
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Chapter 3 – Structure of a SusCD complex from Bacteroides thetaiotaomicron 
3.1. Introduction 
Proteins in the outer membrane (OM) of Gram-negative bacteria often form highly stable β-
barrels which can function as enzymes, signalling proteins or transporters in addition to forming an 
integral part of the membrane. In contrast to those of other Gram-negative species (e.g. E. coli) 
Bacteroidetes outer membrane proteins (OMPs) have gone largely unstudied.  
Bacteroidetes have groups of co-regulated genes organised into numerous polysaccharide 
utilisation loci (PULs) encoding the specific proteins required for sensing, binding, degrading and 
importing glycans (Martens et al., 2009). Individual PULs, from Bacteroidetes found in the HGM, 
have been identified for all known naturally occurring glycans, except cellulose (Martens et al., 
2011). This includes a vast range of polysaccharides varying in size, charge and branching. 
The general model for polysaccharide utilisation, Figure 3.1, involves a surface glycan 
binding protein (SGBP) which binds polysaccharides, however, this protein has been shown to be 
non-essential in many PULs so the exact function is not clear (Tauzin et al., 2016; Cartmell et al., 
2017).  The complex polysaccharides are digested by an extracellular endo-acting carbohydrate 
active enzyme, typically a glycoside hydrolase or polysaccharide lyase. The resulting oligosaccharides 
are bound by a SusD homologue and imported by a SusC homologue, an essential step in the 
utilisation of complex carbohydrates (Shipman et al., 2000). The imported oligosaccharides are then 
digested to monosaccharides by exo-acting carbohydrate active enzymes in the periplasm. The 
monosaccharide products are imported into the cytoplasm where they enter into fermentation 
pathways yielding carbon and energy for the cell. The import of final products across the inner 
membrane is not fully understood within the context of PULs. Some PULs encode major facilitator 
superfamily (MFS) transporters but have yet to be characterised and the size limit for import is 
unknown (eg. monosaccharides or small oligosaccharides). 
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Figure 3.1 General model of polysaccharide utilisation by Bacteroidetes.  
The target polysaccharide is bound by a surface glycan binding protein (SGBP) then digested by an 
extracellular endo-acting carbohydrate active enzyme. The oligosaccharide product is then bound 
by a SusD homologue and imported by a SusC homologue. The oligosaccharide is digested further 
by exo-acting carbohydrate active enzymes in the periplasm and monosaccharides are imported 
into the cytoplasm.  
Sequestering oligosaccharides and monosaccharide products to the periplasm is thought to 
minimise the loss of simple products to other members of the densely populated gut microbiota 
(Cuskin et al., 2015). However, some Bacteroidetes have been found to ‘share’ partially digested 
glycans with other bacteria (Rogowski et al., 2015).  
SusC homologues are predicted to be 22 β-stranded TonB dependent transporters (TBDTs) 
which are thought to interact in the OM with the SusD homologue via the conserved 
tetratricopeptide repeats (TPRs) (Bolam and Koropatkin, 2012). TBDTs are characterised by an N-
terminal globular plug domain which occludes the channel of the 22-stranded β-barrel and a 
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conserved TonB box sequence of amino acids at the N-terminal which interacts with TonB. The IM 
protein TonB forms a complex with ExbB and ExbD which altogether provide the energy required for 
transport by TBDTs (Hickman et al., 2017).       
This study focused on Bacteroides thetaiotaomicron (B. theta), one of many anaerobic, 
Gram-negative Bacteroidetes which are dominant in the human gut microbiota (HGM). There are 
103 SusC homologues encoded by the B. theta genome but the structure and exact function of the 
transporters have not been successfully determined. The findings reported here have implications 
beyond the HGM as the Bacteroidetes phylum are widely distributed in the environment. This 
includes sediments, soil, sea water, on the skin, in the mouth and in the gut of many animals 
(Grondin et al., 2017b). All Bacteroidetes genomes sequenced to date encode SusCD homologues 
(Grondin et al., 2017a).  
 
3.2. Aims 
The aim of this chapter was to identify highly expressed outer membrane proteins from B. 
thetaiotaomicron. The second objective was to purify, crystallise and solve the structure of a SusCD 
homologue from B. thetaiotaomicron. 
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3.3. Results 
3.3.1.  Bacteroides thetaiotaomicron outer membrane proteins 
3.3.1.1.  Comparing E. coli and B. theta outer membrane proteins  
Outer membrane proteins from E. coli and B. theta grown on minimal and rich media were 
visualised using SDS-PAGE (Figure 3.2). B. theta did not express classical trimeric porins at sufficient 
levels to be visible by SDS-PAGE. Trimeric general porins are abundant in E. coli and dissociate to 
monomers when boiled (OmpF/C highlighted by red boxes). In contrast, B. theta expressed many 
proteins over 100 kDa (Figure 3.2) suggesting a fundamentally different mechanism for nutrient 
acquisition. This result was expected as the B. theta genome does not encode any obvious OMP 
homologues. There are fewer differences between the two B. theta conditions than the E. coli which 
may be because the rich and minimal media used for B. theta both contained glucose which likely 
elicits the same level of catabolite repression.  
 
Figure 3.2 SDS-PAGE of total outer 
membrane proteins from E. coli and B. 
theta.  
E. coli (lanes 1, 2, 5, 6,) and B. theta 
(lanes 3, 4, 7, 8). Rich medium (even 
numbered lanes) and minimal medium 
(odd numbered lanes). Abundant E. coli 
trimeric porins OmpF/C are highlighted 
by red boxes. Samples 5-8 were boiled 
before loading and molecular weight 
(MW) marker indicates approximate 
protein sizes in kDa. 1 litre of bacteria 
was grown in each medium. The cells 
were lysed and processed as outlined in 
Methods 2.8.3. The samples were then 
loaded onto an anion exchange 
Resource Q column, in 0.6 % LDAO, as 
described in 2.8.5, then eluted in 4 X CV 
of 1 M NaCl. Approximately 10 ug of 
the total protein was loaded on the gel. 
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3.3.1.2. Purification and Identification of B. theta OMPs 
Wild-type (WT) B. theta grown on rich Tryptone Yeast Glucose (TYG) media was processed as 
described previously (Methods 2.8). A final solubilisation step was carried out using 1 % LDAO 
detergent before separation by anion exchange using a Resource Q (6 ml) column.  
A shallow salt gradient (initially 50 mM to 1 M NaCl over 120 ml) separated the proteins as 
shown in the chromatogram in Figure 3.3A. The peak samples (labelled A-D) were analysed using 
SDS-PAGE, boiled (B) and non-boiled (NB, Figure 3.3B). This gel indicated many of the OMPs are 
heat-modifiable as bands appeared at different MW and extra bands are visible after boiling. The 
high molecular weight bands, highlighted by the red boxes, were excised and identified by Dr Joe 
Gray, of Newcastle University, using LCMS-MS. 
Bands 1 and 5 contained BT2409 and BT3560, respectively, which were predicted to be 
TBDTs. Band 3 was identified as BT2260, a SusC homologue from an operon with two predicted 
enzymes of unknown function and two hypothetical proteins. Bands 2 and 4 were BT1440 and 
BT2268, respectively. These proteins were both identified as SusC homologues each expressed with 
a SusD homologue partner. However these SusCD homologues are expressed alone, rather than as 
part of PULs, and we termed these orphan SusCD homologues.   
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Figure 3.3 Identification of OMPs from B. theta grown on TYG rich medium.  
A: Anion exchange chromatogram of B. theta total outer membrane proteins separated on a 
ResourceQ column after extraction using LDAO. The main peaks were labelled A-D B: SDS-PAGE of 
peak fractions both boiled (B) and not boiled (NB). Bands highlighted by the red boxes were 
excised and identified using peptide mass fingerprinting. Band 1: BT2409, Band 2: BT1440, Band 3: 
BT2260, Band 4: BT2268, Band 5: BT3560. Molecular weight (MW) marker indicates protein sizes 
in kDa. 
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A SusC homologue of particular interest was BT1763, from the well characterised B. theta 
PUL which targets the fructo-oligosaccharide levan (Introduction 1.3.2). The PUL is expressed in 
response to growth on the monosaccharide fructose (Sonnenburg et al., 2010) which is readily 
available in large quantities making BT1763 a tractable SusC target for large scale native expression. 
Therefore, the process of purifying and identifying B. theta OMPs was repeated using bacteria grown 
on minimal media containing 0.5 % fructose as the only carbon source (MM-Frc). The anion 
exchange chromatogram in Figure 3.4A shows proteins eluted as the salt concentration increased. 
The peaks labelled A and B were further purified using gel filtration. The resulting fractions were 
analysed boiled (B) and non-boiled (NB) using SDS-PAGE shown in Figure 3.4B. As with the previous 
samples, the high molecular weight bands highlighted by red boxes were excised and identified by 
Dr Joe Gray, of Newcastle University, using LCMS-MS. 
Band 2 was identified as containing the protein of interest BT1763SusC and another SusC-like 
BT2268. This was also isolated from the rich media outer membrane purification. Bands 3 and 4 
contain the SusD homologues BT1762 and BT2269, respectively. Band 1, which was non-boiled, 
contained all four of these proteins. This indicated that SusC and SusD homologue pairs interact very 
strongly such that they co-purify. This interaction is not compromised by strong detergents or SDS 
and separation of SusCD complex requires boiling. The two SusCD homologue pairs have very similar 
predicted isoelectric points (5.14 and 5.20), making them very difficult to separate without the 
introduction of affinity tags fused to the expressed protein.  
The peak B sample (Figure 3.4B) showed a single large molecular weight smear around 160 
kDa in the non-boiled sample, which became several smaller bands when boiled, indicating a very 
stable protein complex. The highlighted bands were identified as another SusCD homologue pair 
BT2264SusC in band 5, and BT2263SusD in band 6. This complex is relatively straightforward to express 
and purify directly from WT B. theta as it binds to the anion exchange column relatively tightly in 
comparison to the other outer membrane proteins. 
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Figure 3.4 Identification of OMPs from WT B. theta grown on MM-Frc. 
A: Ion exchange chromatogram of WT B. theta total OMPs separated on ResourceQ after 
extraction using LDAO. The peaks labelled A and B were further purified by gel filtration B: SDS-
PAGE of peaks A and B. Boiled (B) and non-boiled (NB) samples. Bands highlighted by the red 
boxes were excised and identified using peptide mass fingerprinting. Band 1: BT1762SusD, 
BT1763SusC, BT2268SusC and BT2269SusD, Band 2: BT1763SusC and BT2268SusC, Band 3: BT1762SusD, 
Band 4: BT2268SusD, Band 5: BT2264SusC, Band 6: BT2263SusD. Molecular weight (MW) marker 
indicates protein sizes in kDa. 
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3.3.2. Obtaining the Structure of the BT2261-4 outer membrane complex  
3.3.2.1.  Purification and crystallisation of the BT2261-4 complex 
Based on the initial purification and identification of outer membrane proteins directly from 
B. theta, BT2264SusC and BT2263SusD were targeted because the proteins were highly expressed and 
could be purified sufficiently for crystallisation using anion exchange (Peak B, Figure 3.4). WT B. 
theta was grown on MM containing 0.5 % (w/v) fructose (MM-Frc). To avoid overloading the 
column, two or three litres of culture were used for each purification by anion exchange 
chromatography (Methods 2.8.3 and 2.8.5).  An example chromatogram is shown in Figure 3.5A. 
Consistent with the purification to identify OMPs from B. theta grown on MM-Frc, the trace shows 
an isolated peak eluting at very high salt concentrations containing BT2263SusD and BT2264SusC 
(highlighted by red box, Figure 3.5A). The equivalent anion exchange samples from each purification 
were pooled and further purified by gel filtration. The yield for purification of the complex was up to 
1 mg per litre of culture. An example SDS-PAGE, Figure 3.5C, showed that the purified product 
contained four distinct proteins BT2261-4 from the same locus (Figure 3.5B). The SusCD homologue 
pair was identified along with two small outer membrane lipoproteins of unknown function BT2261LP 
and BT2262LP (16 kDa and 24 kDa, respectively) which co-purified with the target proteins BT2263SusD 
and BT2264SusC. The locus does not contain any further co-regulated proteins, such as enzymes or 
putative glycan binding proteins, making it impossible to predict the target ligand of the complex.  
During one purification of the complex, the protein precipitated following anion exchange, 
therefore DM detergent was added to the pooled fractions to a final concentration of 1 %. DM was 
subsequently used instead of LDAO for the first gel filtration purification step of later purifications. 
The sample was buffer exchanged by a second gel filtration into C8E4 buffer for crystallisation 
screens.   
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The anion exchange purification, followed by size exclusion chromatography (SEC) was 
sufficient to provide enough pure protein for crystal screens. An initial hit in the MemGold2 screen 
(Molecular dimensions) contained the most promising crystals based on diffraction patterns from 
Diamond Light Source (DLS). The condition was 19 % PEG3350, 50 mM Tris pH 8 and 0.2 M 
Magnesium formate dihydrate. Several rounds of optimisation were carried out using the hanging 
drop vapour-diffusion method (Figure 3.5D). Two data sets were collected at the Diamond 
synchrotron with two different space groups, P212121 and P1. Data was collected to a resolution of 
3.4 Å for a P212121 space group and 2.8 Å. for a P1 space group.  
The PDB already contained a structure of the lipoprotein BT2261LP (PDB ID 3H3I) but BT2262LP 
had not been solved. Several SusD homologue structures have also been elucidated but not 
BT2263SusD at this stage. However BT2261LP and BT2263SusD ,which could be feasibly solved by 
molecular replacement, are only one third of the overall complex (70 kDa of 202 kDa total). This 
made solving the overall complex by molecular replacement difficult.  
A method was designed to produce BT2261-4 with selenomethionine (SeMet) from WT B. 
theta (Methods 2.8.2) based on a protocol developed for SeMet incorporation by inhibition of 
methionine biosynthesis (Van Duyne et al., 1993). The protein was purified, screened in various 
crystal conditions, then optimised as before. The SeMet substituted complex produced diffracting 
crystals but none of the datasets (SAD and MAD) provided sufficient quality phases to solve the 
structure.  The anomalous signal was also weak suggesting a low level of SeMet incorporation by B. 
theta.   
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Figure 3.5 Purification of BT2261-4 from WT B. theta.  
A: Ion exchange chromatogram of B. theta total outer membrane proteins separated on 
ResourceQ after extraction using LDAO. The highlighted peak was further purified by gel 
filtration B: Schematic diagram of BT2261-4 gene locus. Arrows are to scale and the arrow 
heads indicate gene orientation C: SDS-PAGE of the purified protein. Boiled (B) and non-
boiled (NB) samples. Molecular weight (MW) marker indicates protein sizes in kDa. D: 
Optimised crystals of BT2261-4 complex. 
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3.3.2.2. BT2262LP and BT2263SusD structures 
To improve the chance of finding a solution for the overall BT2261-4 structure, the individual 
structures of soluble BT2262LP and BT2263SusD were solved. Each protein was cloned, without the 
native Type II signal sequence or N-terminal cysteine which is used to append the protein covalently 
to the outer-membrane, into a pET9 vector for overexpression in the periplasm of E. coli. The 
proteins were purified by immobilised metal affinity chromatography (IMAC) and the His-tag cleaved 
using TEV protease (Figure 3.6A and B, E1 and +TEV). A second round IMAC was used to remove the 
tag, and any undigested BT2262LP or BT2263SusD with the cleaved protein collected in the flow 
through and wash (Figure 3.6A and B, FT+W).  A final gel filtration step was used before the proteins 
were concentrated.  
Several crystallisation screens (Molecular Dimensions) were set up using a Mosquito 
crystallisation robot (TTP Labtech). Initial hits were optimised using vapour diffusion hanging drops 
and crystals were harvested by Prof. Bert van den Berg.  The crystals of BT2262LP were produced in 2 
M ammonium sulphate, 0.1 M HEPES (pH 7.5), 2 % (w/v) PEG400 (Figure 3.6C). BT2263SusD crystal 
conditions were 0.2 M sodium acetate trihydrate, 0.1 M Tris (pH 8.5), 30 % (w/v) PEG4000 (Figure 
3.6D). Data sets were collected by Dr Arnaud Baslé at the DLS.  
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Figure 3.6 Purification and crystallisation of soluble BT2262LP and BT2263SusD 
SDS-PAGE analysis of samples from the purification of BT2262 lipoprotein (A) and BT2263 SusD 
homologue (B). Initial IMAC elutions (E1) were incubated with TEV protease overnight (+TEV) to 
cleave the His-tag. Pure protein lacking the His-tag was collected in the flow through and wash 
(FT+W) of a second IMAC purification. Gel filtration (GF) was used as the final purification step.  C: 
Crystals of BT2262 lipoprotein produced in 2 M ammonium sulphate, 0.1 M HEPES (pH 7.5), 2 % 
(w/v) PEG400 D: Crystals of BT2263 SusD homologue produced in 0.2 M sodium acetate trihydrate, 
0.1 M Tris (pH 8.5), 30 % (w/v) PEG4000 
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Figure 3.7 Structures of BT2262LP and BT2263SusD 
X-ray crystal structures of BT2262LP PDB ID: 5FQ3 (A) and BT2263SusD PDB ID: 5FQ4 (B) coloured 
rainbow from blue (N-terminus to red (C-terminal). The structures have been rotated 180° around 
the vertical axis between the two images. 
 
 The NT domain from the BT2261-64 complex structure of the BT2262LP was built manually by 
Bert van den Berg and consequently used as a MR model to solve the full length recombinant 
protein structure (Figure 3.7A). BT2262LP is 24 kDa overall and consists of two domains, an N-
terminal β-strand domain and a C-terminal eight stranded β-barrel.  
 BT2263SusD was solved by MR using BT2259 SusD as a search model (PDB ID: 4Q69 26 % 
identity to BT2263SusD) to a resolution of 1.9 Å. The structure in Figure 3.7B shows the eight 
conserved helices forming the four tetratricopeptide repeats (TPRs) typical of SusD homologues. The 
remaining loops and helices are highly variable as with the other homologue structures.  
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3.3.2.3. BT2261-4 Complex Structure 
Without anomalous data or a suitable molecular replacement model for BT2264SusC solving 
the overall complex was extremely challenging. The final BT2261-4 structure solved by Bert van den 
Berg required several rounds of manual building for BT2264SusC and BT2262LP. 
MR trials using existing structures within the PDB were unsuccessful; FepA (PDB ID 1FEP 14 
% identity to BT2264SusC), BT2259 SusD (PDB ID 4Q69 26 % identity to BT2263 SusD) and BT2261LP (PDB 
ID 3H3I). FepA is a TBDT from E. coli which transports iron binding siderophores and the structure 
was solved in 1999 (Buchanan et al., 1999). Phaser was used to find a definite MR solution for a P1 
crystal of the BT2261-4 complex using BT2263 SusD (Figure 3.7B), and sculptor-modified FepA as 
search models (Adams et al., 2010). Using the BT2261LP structure, manual building of BT2264 SusC and 
the N-terminal of BT2262 LP along with the 2-fold non-crystallographic symmetry (NCS) the structure 
was completed with Rfree ~28 % (Figure 3.8A and B). 
The BT2264 SusC (Figure 3.8C) has a typical, although larger than usual, TBDT structure; a 22-
stranded β-barrel and N-terminal plug domain. Two BT2264 SusC proteins form a dimer and the 
BT2263 SusD proteins form an extracellular lid over each barrel to produce the overall complex 
structure (Figure 3.8A). The dimerization did not appear to be a crystallographic artefact as it was 
observed in three different crystal forms and was later confirmed by mass spectrometry (carried out 
by Dror Chorev, Oxford University). 
The SusCD pair had a large interface surface area of approximately 3,800 Å2 which included 
fifty hydrogen bonds and three salt bridges. BT2263 SusD did not undergo any conformational changes 
upon binding to BT2264 SusC as the recombinant structure of BT2263 SusD aligned with the complex 
structure (Figure 3.9A). The interface between the C and D of each pair included the highly variable 
substrate binding region of SusDs rather than the four conserved tetratricopeptide (TPR) repeats 
that had been predicted to be the site of interaction (Figure 3.9). 
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BT2261LP and BT2262LP are small 8-stranded β-barrel lipoproteins located on the peripheral 
of the complex (Figure 3.8A and B). There is only one poorly ordered copy of BT2262 LP visible within 
the structure but there are two BT2261LP copies. BT2261 LP, BT2262 LP and BT2263SusD have N-terminal 
linker segments, leading to their lipid anchors, which remain closely associated with BT2264SusC. 
 
Figure 3.8 Overall architecture of the BT2261-4 complex.  
A: Cartoon view of the complex dimer in the outer membrane (OM) PDB ID: 5FQ8 B: Surface 
representation of the complex looking down from outside of the cell C: BT2264 SusC architecture 
highlighting the plug domain (dark blue) and large extracellular loops; L1 (green), L3 (cyan), L7 
(orange), L9 (pale pink), L10 (brown) and L11 (red). The N-terminal 10 residues and lipid anchor of 
BT2263 SusD are shown as magenta stick models D: The structure of the BT2264 SusC monomer as in 
C shown from the side view (Modified from Glenwright et al. 2017).  
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Figure 3.9 The SusC-D interaction involves the ligand-
binding face of SusD  
A: Cartoon overlay of BT2263 SusD in isolation coloured 
rainbow from blue (N-terminal) to red (C-terminal) on 
BT2263 SusD within the BT2261-4 complex (magenta). 
The four TPRs are labelled and BT2264SusC is shown as a 
translucent surface B: Superposition of BT2263 SusD 
(magenta) with the archetypal SusD BT3701 (grey, PDB 
ID: 3CKB) viewed from the bottom (top image) and side 
(bottom image - as in A). Bound maltotriose in BT3701 
shown as a space-filling model (carbon black, oxygen 
red) C: BT2263 SusD with residues forming hydrogen 
bonds and salt bridges with BT2264 SusC coloured yellow 
D: Superposition as in B with the putative peptide 
ligand of BT2261-4 included (dark green), showing 
binding site overlap. Figure from Glenwright et al. 
2017.  
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The interface of BT2264SusC and BT2263SusD contained a well-defined stretch of electron 
density approximately 30 Å in length (Figure 3.10). The density cannot be accounted for by any 
components of the media or chemicals used for protein purification and crystallisation. The density 
was modelled well by a ten residue peptide although the sequence is ambiguous at 2.75 Å resolution 
(Figure 3.10). The weak density for several side chains suggests a heterogeneous group of peptides 
rather than one specific sequence was bound by the complex. The peptide has been modelled by ten 
glycine residues in Figure 3.10. The ligand survived several purification steps including the use of 
strong detergent which indicates the peptide is tightly bound and most likely originated from B. 
theta. The ligand was bound at the BT2264SusC and BT2263SusD interface in a cavity which was not 
solvent accessible (Figure 3.10A). Nine out of ten residues of the putative peptide ligand backbone 
interact via hydrogen bonds with either BT2264SusC or BT2263SusD (Figure 3.10B).  Interactions with 
BT2264SusC include the hinge loop (L7 orange) and the plug loop (dark blue).  
 
 
Figure 3.10 Ligand bound to the BT2261-4 complex.  
A: BT2261-4 (side view) showing BT2264 SusC (yellow), BT2263 SusD (magenta), BT2262LP (lilac) and the 
putative peptide ligand in green. B: Close-up of the ligand binding site showing BT2264 SusC (yellow) 
and BT2263 SusD (magenta) residues forming hydrogen bonds with the peptide backbone. Loop L7 
(orange) of BT2264 SusC and the plug loop (dark blue) also interact. The 2Fo − Fc density for deca-
glycine is shown as a blue mesh at 1.5σ (From Glenwright et al. 2017). 
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3.3.3.  Investigating BT2261-4 regulation and function 
Identification of the ligand was unsuccessful by native mass spectrometry (carried out by 
Dror Chorev, Oxford University) which supports an ensemble of bound peptides. Several other 
methods were used to attempt to shed light on the identity of the bound molecule. 
3.3.3.1. Attempting to identify the ligand of BT2261-4 
The BT2261-64 complex was boiled for 5 minutes and analysed using SDS-PAGE (BOLT Bis-
Tris 12 % acrylamide, ThermoFisher) with the aim of separating a low MW band (1-2 kDa) for 
identification of the peptide by mass spectrometry (Figure 3.11). However there were no obvious 
protein bands small enough to be the ligand.   
 
Figure 3.11 SDS-PAGE gel of BT2261-4 complex.  
20 µg and 30 µg of the total BT2261-4 complex analysed, after boiling, using a 12 % acrylamide gel 
(BOLT 12 % Bis-Tris gel with MES Buffer, ThermoFisher).   
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To further explore the capacity of BT2263SusD to bind peptides isothermal titration 
calorimetry (ITC) was utilised. This method has been routinely used to measure the binding of 
proteins, such as SusD homologues, to the target glycans or oligosaccharides.  BT2263SusD was cloned 
without the NT Type II signal sequence into pET28a with an N-terminal Hisx6-tag and expressed in 
BL21 E. coli cells. Following purification by IMAC, binding of the protein to synthetic peptides was 
investigated using ITC. The peptides, GSSGGQNEGG and GDSGSKQKKG, were designed according to 
best fit for the density found in the complex structure (Figure 3.10B). However, BT2263SusD, the 
respective SusD homologue of the transport complex, showed no affinity for either peptide tested 
(Figure 3.12).  
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3.12 BT2263SusD binding affinity to synthetic peptide ligands.  
A: 37 µM BT2263SusD against 5mM GSSGGQNEGG B: Peptide only control C: BT2263SusD against 
5mM GSSGGQNEGG minus control data. D: 46 µM BT2263SusD against 10mM GDSGSKQKKG E: 
Peptide only control F: BT2263SusD against 5mM GDSGSKQKKG minus control data. The top half of 
each panel shows raw ITC heats of titration with ligand while the bottom half shows integrated 
peak areas. ITC was carried out in 20 mM HEPES pH 7.5 at 25 °C (Methods 2.12.2). 
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3.3.3.2. Using BT2264SusC knockout to find protein function   
Deleting or disrupting a gene to prevent expression of a protein of interest can provide clues 
to the function of the protein if there is a growth defect observed. Therefore a knockout of 
BT2264SusC was produced using pExchange-tdk. The gene was removed by ‘sewing’ together 1000 bp 
upstream and downstream regions of the genome (Methods 2.5.4.3, Figure 2.1). The resulting 
hybrid PCR product was then inserted into pExchange-tdk which is used to produce B. theta 
mutations by homologous recombination (Methods 2.6.1, Figure 2.2). The Δbt2264 strain growth on 
TYG and minimal media with 0.5 % fructose (MM-Frc) was compared with WT B. theta (Figure 3.13). 
There does not appear to be any growth phenotype associated with the deletion of BT2264SusC.  
The BT2261-4 complex was highly expressed and subsequently purified from cells grown on 
MM-Frc however BT2264SusC is not essential under such conditions. This may be due to redundancy 
in peptide importers as there are 103 SusC homologues expressed by B. theta over 80 % of which 
have not been characterised. Other bacteria have been shown to express multiple peptide 
transporters, for example, E. coli has three distinct peptide permeases with varying specificities; 
oligopeptide (Opp), tripeptide (Tpp) and dipeptide (Dpp) (Goodell and Higgins, 1987).  
 
Figure 3.13 Growth curves of WT and Δbt2264 B. theta. 
Cells grown on TYG rich media and minimal media containing 0.5 % fructose (MM-Frc). Growth 
was measured by optical density (A600nm) using an automatic plate reader under anaerobic 
conditions at 37 °C. Triplicate wells have been averaged and the error bars represent the standard 
deviation from the mean.  
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3.3.3.3. Investigating upregulation of the BT2261-4 complex 
Clarifying the growth stage and conditions when a protein is highly expressed can provide an 
indication of the function. For this purpose, a FLAG-tag (DYKDDDDK) was added using pExchange-tdk 
to the C-terminus of BT2263SusD (Figure 3.14A) to allow for western blot analysis of the expression of 
the complex at different stages of growth on TYG and MM-Frc.  
BT2261-4 is constitutively expressed during log-phase on MM-Frc and only upregulated on 
TYG rich media during stationary phase as cell viability falls (Figure 3.14B and C). This expression 
pattern is in stark contrast to known glycan uptake systems which are greatly upregulated in 
response to the target glycan (Martens et al., 2011). However the results are supported by previous 
in vitro B. theta data showing upregulation of the BT2261-4 locus under minimal media conditions 
(with glucose or maltotriose) and downregulation in TYG (Sonnenburg et al., 2005).  The expression 
levels of BT2261-4 suggested the complex is required for growth under nutrient stress conditions.  
 
 
Figure 3.14 Western blot analysis of BT2261-4 complex 
expression using FLAG-tagged BT2263SusD.  
A: Diagnostic PCR to test for successful addition of the 
FLAG-tag. WT genomic DNA was used as a negative 
control. L represents the DNA ladder. A product of 1000 
bp indicates insertion of the tag as shown in lane 2.  B: 
Western blot of samples across the growth curve from 
cells grown on TYG rich media and minimal media 
containing 0.5 % fructose (MM-Frc). Lanes 1–6 
represent gel samples from the corresponding cfu time 
points shown in C. Corresponding colony-forming unit 
(cfu) values (n = 3, average ± standard deviation). 
(Adapted from Glenwright et al. 2017). 
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3.4. Discussion 
3.4.1. Bacteroides thetaiotaomicron outer membrane proteins 
B. theta lack the typical abundant porins and alternatively express very large outer 
membrane proteins (Figure 3.2) suggesting Bactroides spp. use a fundamentally different method for 
nutrient acquisition than well studied Gram-negative bacteria such as E. coli. The genome of B. theta 
encodes 103 predicted SusC homologues of which only ~20 have been characterised and all target 
specific glycans (Sonnenburg et al., 2010; Martens et al., 2011; Cuskin et al., 2015; Cartmell et al., 
2017; Ndeh et al., 2017). Therefore, with so many uncharacterised SusC homologues it is possible B. 
theta could import all of the required nutrients via SusCD pairs. However, this is unlikely for small 
molecules, such as monosaccharides, which are probably imported passively rather than by TBDTs.  
3.4.2. BT2261-4 outer membrane complex  
Successful native purification of a highly expressed (~1 mg per 1 l of B. theta) outer 
membrane protein and subsequent structure was incredibly surprising. The high stability of the 
BT2261-4 complex, even in strong detergent, allowed for many rounds of purification and successful 
crystallisation. The presence of a ligand almost certainly facilitated the crystallisation of the complex 
by locking BT2263SusD to BT2264SusC in a closed, less flexible conformation.  
The BT2264SusC structure is the first of a SusC homologue and is a large TBDT; 22 β-stranded 
barrel with an N-terminal plug domain folded into the channel (Figure 3.8). The dimeric structure of 
BT2264SusC was unexpected and remains unique among TBDTs (Noinaj et al., 2010). The relative 
positioning of BT2263SusD and contact at the ligand binding site was also surprising as SusCD 
homologues were predicted to interact via the four conserved TPRs (Bolam and Koropatkin, 2012). 
TPR domains are commonly associated with protein-protein interactions (Allan and Ratajczak, 2011) 
therefore may be important for SusD homologues to interact with other proteins such as surface 
glycan binding proteins (SGBPs) or extracellular enzymes.   
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3.4.3. BT2261-4 upregulation, ligand and function 
BT2261-4 is expected to be a peptide importer based largely upon the electron density of 
the ligand (Figure 3.10B) and the holo-complex MD simulations using a modelled peptide (Figure 
3.15). Binding studies of BT2263SusD against two synthetic ten residue peptides were unsuccessful 
(Figure 3.12) which may be due to the complex requiring a specific sequence to some extent. 
Ambiguity in the density of the ligand was most likely a result of different amino acid sequences 
bound in the crystal. The polymer backbone was clearly well modelled by a peptide, however, which 
implies polyspecific ligand binding of this transporter complex, a trait that would be advantageous 
given the assumed function of the protein as a peptide scavenger during nutrient scarcity. The 
oligopeptide permease (Opp), an ATP-binding cassette transporter from E. coli, requires a substrate 
binding protein OppA to bind and deliver peptides to the transport machinery. OppA binds peptides 
of any sequence, via interactions with the peptide backbone (Guyer et al., 1986; Tame et al., 1995). 
Structures of OppA with peptide bound show the ligand is completely enclosed by the protein, as 
with the binding interface between BT2263SusD and BT2264SusC,  accommodating the various peptide 
side chains in large cavities within the binding protein (Tame et al., 1994).   
Another possible reason for lack of binding observed by BT2263SusD to the synthetic peptides 
is that the protein in complex forms less than half of the binding site. Only 4 residues (E54, Q57, 
Q56, Q71) from BT2263SusD interact with the peptide backbone and the remainder of the binding 
pocket consists of 7 residues from BT2264SusC involving the hinge loop (L7) and a loop from the plug 
domain (Figure 3.10B). Conceivably BT2263SusD in isolation cannot bind the ligand because it does 
not form enough interactions with the peptide backbone and requires BT2264SusC.  
The knockout strain Δbt2264SusC shows no growth phenotype on MM-Frc (Figure 3.13), this is 
most likely due to other transporters targeting peptides. As previously discussed B. theta expresses 
many SusCD homologues which have not been characterised so there is likely to be redundancy 
between the nutrient acquisition systems. Two SusCD homologues BT3238-9 and BT3240-1 are 
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found in operons alongside predicted peptidases BT3237 and BT3242, respectively, suggesting the 
transporters also target peptides. Interestingly, BT3238-9SusCD were isolated from B. theta grown on 
MM-Frc during a purification of BT2261-4 implying this complex could have a similar function.  
BT3238-9SusCD could not be purified sufficiently for crystallisation.  
  The BT2261-4 complex is constitutively expressed during log-phase on minimal media and 
upregulated as cell viability drops (Figure 3.14). This is in contrast to glycan PULs which are 
selectively upregulated in response to the target polysaccharide (Martens et al., 2011). This lends 
evidence to BT2261-4 having a role in peptide scavenging. During stationary phase toxic waste 
products begin to accumulate and nutrient availability decreases, potentially causing cells to lyse, 
releasing their contents. This includes proteins and peptides which Bacteroidetes can use as a 
carbon source or an amino acid source (Mysak et al., 2014). Transporter complexes BT2261-4 may 
provide an advantage to cells to survive these times of stress, the importance of which is 
underpinned by the apparent redundancy of these systems (Figure 3.13). The scavenging function of 
BT2261-4 during nutrient stress is supported by whole-genome transcriptional profiling which 
showed upregulation of the locus in B. theta from mice fed a simple sugar diet as opposed to a 
polysaccharide rich diet (Sonnenburg et al., 2005). 
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3.4.4. Molecular Dynamics 
The ligand-binding interface between BT2264SusC and BT2263SusD was not solvent accessible 
(Figure 3.10A) therefore BT2263SusD must dissociate from the transporter to capture the substrate. 
To investigate this hypothesis the structure was used in unbiased molecular dynamics (MD) 
simulations carried out by Karunakar Pothula at Jacobs University (Bremen, Germany). Simulations 
were carried out in the presence and absence of the peptide (holo and apo-complexes, respectively) 
on the central dimer BT2263-4 (SusCD pair) and the BT2261-4 complex (tetramer and (BT2261–64) × 
2 octamer). For simplicity the MD simulation snapshots presented here only include the dimer 
BT2263-4 (Figure 3.15A and B). 
During the majority of apo-complex simulations BT2263SusD moved in a hinge-like motion 
away from BT2264SusC to expose the ligand binding site (Figure 3.15B). The extent of opening varied 
between individual simulations but in most open states observed BT2263SusD rotates 40-45°. This 
movement caused all interactions with loops L1, L3-5 and L9-11 of BT2264SusC to be lost. The Cα-Cα 
distances between BT2264SusC Asn203 and BT2263SusD Thr296 increased from 6 Å in the closed 
ligand-bound complex to approximately 40 Å in the open ligand-free state (Figure 3.15C).   
BT2264SusC loop L7 moves with BT2263SusD in the MD simulations and was required for most 
of the remaining BT2264SusC-BT2263SusD interactions in the open state (Figure 3.15B). This loop also 
underwent the biggest conformational change between the apo and holo complex simulations with 
the hinge point at the base of L7 near the lipid anchor of BT2263SusD (Figure 3.15B), as such the 
BT2264SusC loop L7 will be referred to as the hinge loop.     
All of the holo-complexes were stable for the duration of the simulations although the 
conformation of the peptide varied substantially between simulations while remaining at the 
BT2264SusC-BT2263SusD interface. This is unexpected because the electron density of the ligand was 
well defined in the crystal structure (Figure 3.10B). The most likely explanation for this inconsistency 
is that the specific peptide sequence used for the simulations is not stable within the binding pocket. 
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This would imply that the BT2261-4 binding and import system is sequence specific to some extent. 
MD simulations of the full BT2261–64 octamer show the dimeric structure of BT2264SusC does not 
obstruct opening of the BT2263SusD ‘lid’. Each monomer appears to be able to open and close 
independently of the other.  
 
Figure 3.15 Molecular dynamics simulations of BT2263-4. Molecular dynamics simulation 
snapshots of holo-BT2263-4 (peptide bound) (A) and apo-BT2263-4 (B) after 0 ns and 500 ns. 
BT2264SusC is yellow, the plug domain is dark blue, the hinge loop is orange and BT2263SusD is 
magenta. The peptide ligand is shown as green spheres. BT2264SusC Asn203 and BT2263SusD Thr296 
Cα atoms are shown as black spheres. C: Average distances versus simulation time between 
BT2264SusC Asn203 and BT2263SusD Thr296 for dimers (green), BT2261–64 tetramers (red), and the 
(BT2261–64) × 2 octamer (blue, from Glenwright et al. 2017). 
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The MD simulations show a possible mechanism for peptides to become bound by the 
complex (Figure 3.15). In the absence of ligand BT2263SusD opens like a lid from BT2264SusC exposing 
the binding site. A loop from the plug domain of BT2264SusC interacts with the peptide via Leu120, 
potentially this could signal to the TonB complex that the binding site is occupied, which then leads 
to TonB induced transport of the peptide into the periplasm (Hickman et al., 2017). The system 
would then require energy to reset back to the original dynamic opening state. Therefore the energy 
from the ExbBD-TonB system is equivalent to stepping on the pedal of the SusCD bin (Figure 3.16).  
 
Figure 3.16 ‘Pedal bin’ mechanism for 
nutrient import by SusCD homologues. 
SusD is coloured magenta, SusC β-barrel is 
yellow, hinge loop is orange and plug 
domain is dark blue. The ligand is shown as 
a wavy green line and the CT domain of 
TonB which interacts with the SusC is 
coloured cyan.  
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Chapter 4 - Acquisition of Levan polysaccharides by Bacteroides thetaiotaomicron 
4.1 Introduction 
The solved BT2261-4 complex is not a classical glycan importer, therefore it is not clear if the 
overall SusCD configuration is relevant for other homologues. To explore this, a well characterised 
easily upregulated PUL was targeted. 
Levan is a β 2,6-linked fructan polysaccharide, which is found in plants and the capsule of 
many bacteria. B. theta expresses a PUL (BT1754-65) encoding all of the proteins required to use 
levan as a carbon source (Bolam and Sonnenburg, 2011). Of these proteins, four are extracellular, 
producing levan oligosaccharides and transporting these across the outer membrane (Figure 4.1). 
Levan polysaccharides are bound by the surface glycan binding protein (SGBP) BT1761 and broken 
into oligosaccharides, by the endo-acting GH32 levanase enzyme BT1760 (Sonnenburg et al., 2010). 
The oligosaccharide products of the enzyme are then bound and imported into the periplasm by the 
SusD homologue BT1762 and the SusC homologue BT1763, respectively.  
BT1760GH32 and BT1762SusD have been previously characterised and both structures solved 
(Zheng, 2009; Sonnenburg et al., 2010; Mardo et al., 2017). The endo-acting enzyme, BT1760GH32, is a 
β2,6-fructan (levan) specific cell surface lipoprotein and essential for B. theta growth on levan 
(Sonnenburg et al., 2010). BT1762SusD binds levan, and a ΔBT1762SusD strain lacking the levan 
oligosaccharide binding SusD homologue has a major growth defect on levan (Sonnenburg et al., 
2010). The levan SGBP BT1761 has been shown to bind levan (Sonnenburg et al., 2010), however the 
affinity of the interaction has not been investigated. Currently there are only three SGBP structures 
in the PDB; SusE from the starch system, BT4661 which targets heparin and BACOVA_02650 from B. 
ovatus which binds xyloglucan (Cameron et al., 2012; Tauzin et al., 2016; Cartmell et al., 2017). 
Therefore characterising BT1761SGBP and obtaining the structure could be very informative with 
regards to glycan acquisition at the cell surface.  
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Figure 4.1 Levan acquisition across the outer membrane of B. theta.  
A: Genetic organisation of outer membrane genes of the levan PUL; arrows shown to scale with the 
direction of the arrow indicating gene orientation. B: Model of levan degradation and transport at 
the cell surface. Proteins coloured as with genes in A. Levan is bound by the SGBP BT1761 and 
partially digested into oligosaccharides by BT1760, an extracellular GH32 (glycoside hydrolase family 
32) lipoprotein. The oligosaccharides are then bound and imported into the periplasm by the SusCD 
homologue BT1762-3. The levan is further digested into fructose in the periplasm and upregulates 
expression of the PUL by interacting with BT1754, a hybrid two-component system (HTCS) in the IM.  
 
As with other PULs from the Bacteroidetes phylum, the SusC homologue BT1763 has never 
been studied due to the relative difficulty of working with integral membrane proteins. How binding 
of levan oligosaccharide by BT1762SusD is coupled to import via the BT1763SusC is also unknown. 
BT1762-3 is an ideal target for studying SusCD homologues within the context of glycan utilisation, 
as the PUL has been characterised and the locus is upregulated by fructose which is cheap and 
readily available. 
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4.2 Aims 
The main aim of this chapter was to purify, crystallise and solve the structure of the SusCD 
complex BT1762-3 from B. thetaiotaomicron. The second objective was to express, purify, crystallise 
and solve the structure of the surface glycan binding protein BT1761 and investigate binding to 
levan. The final aim of this chapter was to solve the structure for the full outer membrane complex 
involved in levan acquisition BT1760-3.   
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4.3 Results 
4.3.1  BT1762-3 SusCD complex 
4.3.1.1 Addition of a His6-tag to BT1762SusD 
As described in Chapter 3 (section 3.3.1.2), the levan targeting SusCD homologues BT1762-3 
were purified from WT B. theta cells grown on MM-Frc. However, the proteins co-purified with 
another SusCD-like pair and could not be isolated by ion exchange or size exclusion chromatography 
due to almost identical size and isoelectric points (Figure 3.4). Preliminary work on SusC homologues 
by Bert van den Berg was unsuccessful in expressing the proteins recombinantly in E. coli and 
currently there is not a suitable expression plasmid for Bacteroides spp. Expression of OM proteins 
within their native bacteria is beneficial because the protein is folded and inserted in the membrane 
in the natural environment. This was advantageous for the purification of BT2261-4 as it was 
possible to purify B2263SusD and two lipoproteins alongside BT2264SusC (Chapter 3).  
To separate BT1762-3 from the other OMPS a Hisx6-tag, in frame with the protein of interest, 
was added to BT1763 in the B. theta genome. Initially, a Hisx6-tag was added to the N-terminus of 
the genomic copy of BT1763SusC after the signal peptide. However, the cells were unable to grow on 
full length levan polysaccharides, suggesting the addition of the tag compromised the function of the 
transporter. Purification of OMPs directly from B. theta (Chapter 3) has shown that SusC and SusD 
pairs interact very strongly and co-purify therefore tagging the SusD protein should also allow 
extraction of the cognate SusC.  Therefore a Hisx6-tag with a 4xAla linker was added to the C-
terminus of the genomic copy of BT1762SusD of WT B. theta. The successful addition of a Hisx6-tag was 
shown using PCR with a Hisx6 primer (Figure 4.2). The 1000bp PCR products produced from genomes 
1, 2, 4, 5 and 6 indicated incorporation of the C-terminal Hisx6-tag into the B. theta genome. 
Sequencing was used to confirm the addition of the tag was in-frame with the protein. The resulting 
tagged strain will henceforth be referred to as CT-HisBT1762SusD. 
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Figure 4.2 PCR analysis to test for successful addition of a His-tag to BT1762SusD. 
PCR from mutated B. theta genomes using a 6xHis reverse primer  
(5’-GTGGTGGTGGTGGTGGTG-3’) and a primer 1000 bp upstream of the mutation  
(5’- AAAGAAGATAACATTCGAGTCGACTGCCCTTACCGGAATCAAC-3’). A 1000 bp PCR 
product indicates successful addition of a His-tag to the C-terminus of BT1762. 
Negative (-ve) controls were WT B. theta genomes and the positive (+ve) control was 
pExchange containing the His-tagged BT1762 insert. The correct size of 1000 bp has 
been labelled on the DNA ladder (L). 
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4.3.1.2 Expression, purification and crystallisation of BT1762-3 
The CT-HisBT1762SusD strain of B. theta was grown on a minimal media containing 0.5 % 
fructose (MM-Frc). The addition of the Hisx6-tag did not affect growth on MM-Frc or MM-Levan 
(Figure 4.14). Following lysis of the cells, the cell free extract was discarded and the membrane 
proteins were solubulised in LDAO overnight (Methods 2.8.3). The sample containing solubulised 
membrane proteins was then collected by ultracentrifugation.  
The tagged BT1762SusD was co-purified with BT1763SusC using IMAC followed by SEC 
(Methods 2.8.6 and 2.8.7).  As with BT2261-4 the complex was stable in 2 % SDS and separated into 
the component proteins upon boiling before SDS-PAGE. However, unlike with the BT2261-64 
complex, the other OM lipoproteins from the PUL (BT1760 and BT1761) did not co-purify with the 
SusCD pair (Figure 4.3A). The isolated BT1763SusC (after boiling) appears as a double band indicating 
there is some degradation of the protein. IMAC of B. theta membrane proteins is highly specific as 
only the tagged complex BT1762-3 is visible by SDS-PAGE. WT B. theta does not produce any protein 
bands on SDS-PAGE following membrane solubilisation and IMAC. 
BT1762-3 was concentrated to 10 mg/ml and tested for potential crystallisation conditions 
using Molecular Dimensions MemGold1 and MemGold2 screens. Positive conditions were further 
optimised by hand using hanging drop vapour diffusion. Crystals were optimised by varying the 
precipitant concentration in 12-22 % w/v PEG 3350, 0.1 M magnesium formate dihydrate and 0.1 M 
MOPS, pH 7 (Figure 4.3B). The crystals were cryo-protected with 20 % glycerol, and a 3.1 Å 
resolution dataset was collected at Diamond Light Source (DLS). A different crystal form (Figure 4.3C) 
was produced in 18-20 % PEG 3350, 0.2 M ammonium nitrate and 50 mM HEPES, pH 7.5. A second 
dataset from this crystal form was collected to a resolution of 3.0 Å.  
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Figure 4.3 Purification and crystallisation of BT1762-3 SusCD complex  
A: SDS-PAGE of BT1762-3 purified by IMAC followed by size exclusion chromatography 
from the CT-HisBT1762SusDstrain. The sample is shown boiled (B) and not boiled (NB). 
Molecular weight (MW) marker sizes are shown in kDa B, C: Optimised crystals of 
BT1762-3 in 0.1 M Magnesium formate dihydrate, 0.1 M MOPS (pH 7), 17% w/v PEG 
3350 (B) and 50 mM HEPES (pH 7.0), 0.2 M ammonium nitrate, 19% (w/v) PEG 3350 (C). 
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4.3.1.3 Apo structure of BT1762-3 
The crystal structure of BT1762-3 was solved by Bert van den Berg using the previously 
solved soluble BT1762SusD structure (Zheng, 2009) and a sculptor-generated BT2264SusC model (21 % 
identity to BT1763SusC). The structure showed the same relative orientations of BT2261-4 although, 
as expected from the SDS-PAGE (Figure 4.3A), there were no accessory lipoproteins (Figure 4.4). 
BT1763SusC formed a homodimer where BT1762SusD acted as a ‘lid’ capping each transporter.  As with 
the BT2263-4 SusCD structure, binding to BT1763SusC did not require/induce a conformational change 
in BT1762SusD and involved the binding interface of the SusD homologue rather than the conserved 
TPRs (Figure 4.4D). The hinge loop (L7) highlighted in BT2264SusC was conserved in BT1763SusC 
suggesting it may be essential for successful opening of the SusD ‘lid’ as shown in the molecular 
dynamics simulations (Chapter 3, section 3.3.3.5). There was no levan oligosaccharide ligand bound 
in the BT1762-3 structure which was to be expected due to the lack of substrate (levan) during cell 
growth. The BT1762SusD cap is closed, like the BT2261-4 ligand bound structure, almost certainly 
because crystallisation favors compact, stable protein states.  
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Figure 4.4 Apo structure of BT1762-3 SusCD complex. 
A: Cartoon views of the overall BT1762-3 structure from the side within the OM PDB ID: 5T3R  
B: BT1762-3 from the outside of the cell (rotated 90 °C from A) C: BT1762-3 from inside the cell 
(rotated 180 °C from B) In A-C BT1762SusD is shown in orange/purple and BT1763SusC is shown in dark 
blue/green. D: Cartoon overlay of soluble BT1762SusD structure (rainbow) and BT1762SusD within 
BT1762-3 (red). BT1763SusC is shown in green. TPR motifs in BT1762SusD are labelled. Adapted from 
Glenwright et al. 2017 
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Surprisingly, there was no electron density for the plug domain of BT1763SusC (Figure 4.4C). 
SDS-PAGE comparison of three different preparations of BT1762-3 (Figure 4.5A) showed degradation 
of the BT1763SusC of the sample which produced diffracting crystals (Figure 4.5A, lane 3). SDS-PAGE 
of crystal-containing drops (Figure 4.5B) showed the protein had a molecular weight approximately 
30 kDa lower than full length BT1763SusC (Figure 4.5A). Prolonged incubation of freshly isolated 
complex at room temperature also led to spontaneous degradation of the plug domain and 
DUF4480, suggesting the plug of the SusC was cleaved by a co-purified protease contaminant.   
 
 
 
Figure 4.5 SDS–PAGE of BT1762-3 SusCD showing degradation of the BT1763SusC.  
All samples were boiled to separate the two proteins of the complex. Molecular weight (MW) 
marker shows approximate protein sizes in kDa. A: SDS-PAGE comparison of three BT1762-3 
protein samples from different purifications. All protein was flash frozen in liquid nitrogen and 
stored at -80 °C. Lane 3 shows BT1763SusC degradation which had not occurred with the other 
samples. The complex in lane 3 produced the well diffracting crystals (Figure 4.3) B: BT1762-3 
protein from a drop containing crystals showing severe degradation of BT1763SusC  
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4.3.2 BT1762-3 SusCD complex with bound levan oligosaccharide. 
4.3.2.1 Growth of CT-HisBT1762SusD with added Levan 
BT2261-4 with ligand bound, and apo BT1762-3 protein were successfully purified directly 
from B. theta. Following this, the aim was to purify BT1762-3 with levan oligosaccharides bound, 
by a similar method. Initially, CT-HisBT1762SusD cells were grown on MM-Frc for 18 – 20 hours as 
before. Levan (0.05 %) was then added to the cultures, under anaerobic conditions, and the cells 
were incubated for a further 10 minutes at 37°C. Supernatant from the cultures was boiled and 
analysed by TLC to ensure levan remained in the growth medium (Figure 4.6). The cultures were 
harvested and purified using IMAC as previous. This process was repeated several times but failed 
to return sufficient protein for crystallisation (<10 % of expected yield). The cells were stickier 
than usual which could suggest that the addition of the levan polysaccharide may have altered the 
capsule of B. theta (Tzianabos et al., 1992) and disrupted the purification. Alternatively, the 
presence of levan may have recruited other outer membrane proteins from the PUL (BT1760GH32 
and BT1761SGBP) to produce a complex which could have obstructed the Hisx6-tag on BT1762SusD. 
 
Figure 4.6 TLC showing the supernatant from B. theta grown on MM-Frc plus levan 
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CT-HisBT1762SusD cells were grown on MM-Frc for 18 – 20 hours. 0.05 % levan was added and the 
cells were incubated for 10 minutes before harvesting. The supernatant was boiled and 2 μl was 
analysed by TLC. The control sample was taken immediately following addition of levan and 
numbers 1-6 represent different culture bottles. The remaining fructose and levan in the samples 
are labelled.  
4.3.2.2    Production and purification of levan oligosaccharides 
A practical alternative to purifying BT1762-3 with substrate bound was to purify the protein 
and oligosaccharides separately and co-crystallise. The BT1760GH32 endo-acting levanase from the B. 
theta levan PUL was expressed in E. coli and purified using IMAC (Figure 4.7A). 100 nM of the 
enzyme was then used to partially digest levan polysaccharides from Erwinia herbicola (Sigma-
Aldrich) by incubating at 37 °C for 20 minutes (Figure 4.8B, Methods 2.12.4). BT1760GH32 appears to 
preferentially produce fructotriose (Figure 4.7B) which has been shown previously (Sonnenburg et 
al., 2010). The resulting oligosaccharides were separated using size exclusion chromatography (P2 
Biogel, Biorad) and every fifth fraction was analysed by TLC (Figure 4.7C). Previous ITC data had 
shown BT1762SusD in isolation requires at least seven fructose molecules for levan binding, although 
affinity for levanheptaose is very weak (Zheng, 2009). The TLC standards facilitated estimation of 
oligosaccharide length in each fraction. Samples containing approximately 6-14 fructose units from 
fractions 90-125 (highlighted by box, Figure 4.7C) were freeze-dried and pooled for co-crystallisation 
with BT1762-3. 
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Figure 4.7 Production and purification of levan oligosaccharides. 
A: Example SDS-PAGE of BT1760GH32 samples following overexpression in E. coli BL21 and IMAC 
purification. Cell free extract (CFE), flow through (FT), wash (W), elution with 5 mM imidazole (E5) 
and elution with 100 mM imidazole (E100). The major band at ~57kDa in CFE and E100 lanes is the 
expected MW of BT1760GH32. Molecular weight (MW) marker shows approximate protein sizes in 
kDa. B: 500 mg (5 mg/ml) Levan from E. herbicola shown before (0m) and after 20 minute 
incubation (20m) with 100 nM BT1760GH32. Standards (S) shown are 2 mg/ml (each) fructose (Frc), 
sucrose (Suc), kestose (K3), kestotetraose (K4) and kestopentaose (K5) used as comparison. K3, K4 
and K5 are 2,1-linked fructo-oligos because 2,6-linked levan oligos cannot be purchased. C: Partially 
digested levan from A separated by size exclusion chromatography. TLC shows every fifth fraction 
and standards (S) as in A. The fractions highlighted by the box (90-125) were pooled for co-
crystallisation. 
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4.3.2.3 Co-crystallisation of BT1762-3 with levan oligosaccharides 
A large-scale MM-Frc growth of CT-HisBT1762SusD B. theta and purification of BT1762-3 was 
carried out as before with the addition of protease inhibitors (cOmplete, EDTA-free Protease 
Inhibitor Cocktail Tablets, ROCHE) to the cells prior to lysis and during membrane solubilisation 
(Figure 4.8A). The protein was concentrated to 12 mg/ml and incubated with 2.5 mM levan 
oligosaccharides for 1 hour before crystal screens were set up. Additional detergent (0.2 % LDAO) 
was added to half of the crystal drops and produced crystal hits (Figure 4.8B), which were then 
optimised. Crystals grown in 0.15 M sodium formate, 0.1 M HEPES pH 7.2, 18 % PEG 3350, showed 
diffraction when tested in-house and were sent to DLS for data collection.       
 
Figure 4.8 Co-crystallisation of BT1762-3 with levan oligosaccharides 
A: SDS-PAGE of BT1762-3 purified by IMAC followed by size exclusion chromatography. 
The sample is shown boiled (B) and not boiled (NB). Molecular weight (MW) marker 
sizes are shown in kDa B: Initial crystal hits of BT1762-3 (12 mg/ml) with 0.2 % LDAO 
and 2.5 mM levan oligosaccharides. Crystallisation conditions; 0.05 M NaCl, 0.1 M 
Sodium phosphate pH 6, 16 % PEG 4000 (top panel), 0.15 M sodium formate, 0.1 M 
HEPES pH 7.2, 18 % PEG 3350 (middle panel), 0.1 M Sodium cacodylate pH 6.5, 24 % 
(w/v) PEG 1500.  
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4.3.2.4 Structure of BT1762-3 with levan oligosaccharide bound 
Co-crystallisation of BT1762-3 with the levan oligosaccharides was successful and led to a 
structure with the ligand bound. The structure was solved by Bert van den Berg using MR with the 
apo BT1763SusC structure and the plug domain of BT2264SusC used as search models (Figure 4.9). The 
overall structure, solved using data to 2.9 Å resolution, was almost identical to the apo structure, 
although the plug domain was intact within the barrel of BT1763SusC (Figure 4.9). An overlay of the 
two BT1763SusC structures, showed small variations in the positioning of extracellular loops but no 
significant conformational change upon binding the levan oligosaccharide (Figure 4.10). The root 
mean square deviation of atomic distances (RMSD) for the two structures is 1.35 Å (all atoms).  
The levan binding site contains five β2,6-linked fructose units (Figure 4.11). The binding site 
is completely enclosed between the two proteins (Figure 4.11A). Interactions with levan include 
seven residues from BT1762SusD (D59, N61, D85, W103, C316, R386, Y413) and six residues from 
BT1763SusC (E404, D431, R432, F674, N926, V927).   
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Figure 4.9 Overall BT1762-3 structure with levan oligosaccharide bound. 
 A: Cartoon view of the overall BT1762-3 structure from the side within the OM. BT1762SusD shown 
in orange/purple and BT1763SusC shown in dark blue/green. The bound levan oligosaccharide is 
shown in black. B: BT1762-3 from inside of the cell showing the plug domain intact (coloured as in 
A). C: BT1763SusC monomer shown from outside the cell (rotated 180 °C from B) with large 
extracellular loops labelled. The barrel of the transporter is shown in orange, the plug domain is 
dark blue and the hinge loop (L7) is yellow. Helices are shown as cylinders. The bound levan 
oligosaccharide is shown as green sticks.   
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Figure 4.10 Overlay of BT1763SusC apo and ligand bound structures. 
A: BT1763SusC truncated apo structure (orange) aligned with the ligand bound BT1763SusC including 
the intact plug domain (blue) shown from the side. B: The overlay shown from the extracellular side 
top down view, coloured the same as in A. Helices are shown as cylinders. 
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Figure 4.11 Levan binding site within BT1762-3. 
A: Levan oligosaccharide shown as spheres within BT1762-3. BT1762SusD is purple and BT1763SusC is 
blue with the hinge loop shown in yellow. B: Close-up of the levan binding site within the SusCD 
complex. Levan shown in green, binding residues from BT1762SusD are purple and residues from 
BT1763SusC are dark blue. All residues are numbered as for full length proteins including signal 
peptides. The binding site has been rotated 180° around the vertical axis between the two images.  
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4.3.3 Mutating BT1762-3 to investigate function 
4.3.3.1 BT1762SusD binding site mutants 
Previously, Hongjun Zheng produced mutations of BT1762SusD (W103A, C316A, Y413A, 
W414A, W497A) based on the putative binding site of the recombinant structure. The mutants were 
protein was expressed recombinantly and purified using IMAC (Methods 2.7) then tested for binding 
with levan using ITC (Glenwright et al., 2017). Based on the structure of the SusCD complex BT1762-
3 with bound levan (Figure 4.11B), the remaining interacting residues of BT1762SusD were mutated to 
alanine using site directed mutagenesis (Methods 2.5.4.2) and sequenced to ensure each mutation. 
These mutants were also expressed in E. coli, purified and tested for binding to Bacillus levan by ITC 
(Figure 4.12). Six mutations completely disrupt the binding ability of the protein (D59, N61, D85, 
W103A, C316A and R386) and Y413A significantly reduces the affinity of BT1762SusD for levan (Table 
4.1). Two control mutations of tryptophan residues, which were not expected to interact with levan, 
were tested; one close to the binding site (W414A) and one on the opposite side of BT1762SusD 
(W497A). Neither mutation significantly affected the interaction with levan, therefore the lack of 
binding by the other mutants is due to disruption of the binding site rather than affecting the overall 
structure of the protein.  
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Figure 4.12 BT1762SusD mutants binding to levan measured by ITC. 
Bacillus levan (5 mg/ml) was titrated against WT and mutant forms of BT1762 (all ~50µM). All ITC 
was carried out in 20 mM HEPES pH7.5 at 25 °C. Where possible, data was fit using MicroCal 
Origin 7 software. The reduced wild-type titration was carried out in the presence of 1 mM Tris 2-
carboxyethyl phosphine (TCEP). Figure includes data collected by Hongjun Zheng (WT, W103A, 
C316A, Y413A, W414A, W497A) from Glenwright et al. 2017. 
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Table 4.1 ITC data for BT1762SusD mutants binding to levan polysaccharides 
Data from ITC shown in Figure 4.13. No binding observed is abbreviated to NB. 
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4.3.3.2 Introducing BT1762-3 mutations into the B. theta chromosome 
B. theta requires functional BT1762-3 for growth on levan (Sonnenburg et al., 2010), 
suggesting it may be possible to investigate the importance of components of the complex by 
introducing mutations into genomic copies of BT1762SusD or BT1763SusC and analysing growth on the 
fructan.  
The hinge loop (L7 Figure 4.9C and 4.11A) is conserved in both SusCD complexes and 
appears to be important in the molecular dynamic simulations of BT2263-4 (Chapter 3, section 
3.3.3.5). To explore the importance of the hinge loop in SusCD function, the region (residues 667-
696, Figure 4.13A) was removed in the genomic copy of BT1763SusC and replaced with a single glycine 
residue to join the β-strands of the barrel. The B. theta mutant lacking the hinge loop will be 
referred to as ΔHinge-BT1763. 
 
Figure 4.13 B. theta BT1763SusC mutant 
strains. A: BT1762-3 cartoon structure 
showing BT1762SusD in light magenta and 
BT1763SusC in rainbow. The hinge loop (L7) 
highlighted is black. The bound levan 
oligosaccharide is represented as spheres. B: 
Schematic representation of the domains of 
BT1763SusC showing the domain of unknown 
function DUF4480 (blue), TonB box (red), 
plug domain (yellow) and TonB dependent 
transporter (purple). Residue numbers of the 
full length protein are shown for each 
domain. 
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 Over 80 % of B. theta SusC homologues contain a domain of unknown function DUF4480, 
which is unique among TBDTs. DUF4480 is at the N-terminus, immediately before the TonB box 
(Figure 4.13B). The domain did not appear in either of the SusCD complex structures suggesting it 
was disordered and flexible or proteolytically removed. A mutant strain of B. theta without residues 
30-103 of BT1763SusC was produced, and named ΔDUF-BT1763.  
Based on ITC data, W103 is vital for binding of isolated BT1762SusD to levan (Figure 4.13F), 
therefore a strain with the W103A mutation was produced, W103A-BT1762. The BT1762 deletion 
strain (ΔBT1762SusD; Sonnenburg et al. 2010), was used for comparison in the growth assay (Figure 
4.14).  
 All of the strains tested grew similarly on the control minimal media with 0.5 % fructose and 
the addition of the Hisx6-tag did not affect growth of CT-HisBT1762 on levan (Figure 4.14). 
Surprisingly, the growth of W103A-BT1762 on levan was also unaffected by the mutation, suggesting 
redundancy within the binding site. Unexpectedly, ΔHinge-BT1763 only showed a slight increase in 
lag-phase before achieving similar cell density in levan as the WT, suggesting the function of the 
complex is largely unaffected by the loss of the hinge loop (Figure 4.14). Finally, the ΔDUF-BT1763SusC 
mutant showed the most severe phenotype, where no growth was observed after 48 hours. This was 
an even more extreme phenotype than the ΔBT1762SusD strain which eventually grew after a 36 hour 
lag (Figure 4.14).  
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Figure 4.14 Growth of mutant B. theta strains on levan.  
Top panel shows cells grown on minimal media containing 0.5 % fructose. The bottom panel 
shows growth curves on minimal media containing 0.5 % levan. The graphs show WT B. theta 
(red), ΔBT1762SusD (purple), CT-HisBT1762 (black), W103A-BT1762 (blue), ΔHinge-BT1763 (green) 
and ΔDUF-BT1763. Data was collected in triplicate and averaged for each trace. Results are 
representative of at least four individual repeats, errors not shown for clarity. Growth assays were 
performed anaerobically at 37 °C in an automatic plate reader. 
 
The level of BT1762-63 SusCD expression was analysed in the mutant strain ΔDUF-BT1763 
due to the severity of the growth phenotype (Figure 4.14). For this purpose a DUF knockout strain 
was produced which also possessed the C terminal His6-tag fusion with BT1762SusD. For both 
expression tests the original CT-HisBT1762SusD strain was used as a positive control (Figure 4.15).  
Western blot analysis using Anti-His6 antibodies showed expression of BT1762SusD by ΔDUF-BT1763 
at levels comparable with the positive control (Figure 4.15A). A small scale (1 litre) purification of 
BT1762-3 was carried out, as previously described, using IMAC and the resulting samples were 
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analysed using SDS-PAGE (Figure 4.15B). The ΔDUF-BT1763 strain expresses both BT1762SusD and 
BT1763SusC in the OM. While the mutant appeared to express less BT1762-3 than the control strain, 
this was most likely due to lower total protein from the purification as expression levels of 
BT1762SusD were equivalent between the strains by Western Blot (Figure 4.15). These data indicate 
that the major growth defect observed on MM-Levan by ΔDUF-BT1763 was due to a non-functional 
BT1763SusC rather than lack of expression of the complex in the OM.  
 
 
Figure 4.15 Analysing expression of BT1762-3 SusCD by the ΔDUF-BT1763 B. theta strain.  
A: Western blot analysis of BT1762SusD expression using Anti-His6 antibodies. The positive 
(+ve) control was CT-HisBT1762SusD strain and the negative (-ve) control is WT B. theta. B: SDS-
PAGE analysis of BT1762-3 expression from ΔDUF-BT1763 strain compared with the positive 
(+ve) control (CT-HisBT1762SusD). Cells were grown on MM-Frc for 16 hours and protein was 
purified from the OM fraction by IMAC. Protein standard sizes shown are in kDa on both 
panels. 
  
116 
 
4.3.4 BT1761 surface glycan binding protein  
4.3.4.1 ITC of BT1761SGBP with levan  
While SGBPs share the same function they do not show sequence homology, making them 
difficult to identify by bioinformatics techniques (Cameron et al., 2012; Cartmell et al., 2017). Genes 
encoding SGBPs are typically found immediately adjacent to the SusD homologue of the PUL and 
show no homology to known carbohydrate-active enzymes (Martens et al., 2009). BT1761 was 
predicted to be a surface glycan binding protein (SGBP) based on the position within the levan PUL 
and interactions with levan were observed previously by affinity gel (Sonnenburg et al., 2010). An N-
terminal tagged pET28a construct, purified by IMAC (Figure 4.16), was used for ITC binding analysis 
against microbial levan. BT1761SGBP bound Bacillus levan polysaccharides and partially digested 
Erwinia levan (Figure 4.17). This confirmed that BT1761 is a levan binding protein. BT1761SGBP bound 
Bacillus levan with an 8-fold higher affinity than BT1762SusD (Figure 4.17). There also appeared to be 
some interaction between BT1761SGBP and Erwinia polysaccharide levan although the ITC trace does 
not show definitive binding (Figure 4.17). By comparison, BT1762SusD absolutely does not interact 
with full length Erwinia levan in a manner which can be measured by ITC. BT1762SusD shows some 
possible binding to partially digested Erwinia levan, but the affinity was too low to fit (Figure 4.17).  
 
Figure 4.16 Purification of BT1761SGBP 
and BT1762SusD for ITC 
Example SDS-PAGE of BT1761SGBP and 
BT1762SusD samples following 
overexpression in E. coli BL21 and IMAC 
purification. Cell free extract (CFE), flow 
through (FT), wash (W), elution with 5 
mM imidazole (E5) and elution with 100 
mM imidazole (E100). BT1761SGBPis 
expected to be ~50 kDa and 
BT1762SusD is expected to be ~65 kDa 
Molecular weight (MW) marker shows 
approximate protein sizes in kDa. 
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Figure 4.17 Binding of BT1761SGBP and BT1762SusD to levan analysed by ITC.  
5 mg/ml of ligand was titrated against 55 µM of protein. Microbial levan polysaccharide was used 
from two different sources; Bacillus spp. and E. herbicola. The partial digest of E. herbicola levan 
was produced using BT1760 (Figure 4.8A). All ITC was carried out in 20 mM HEPES pH7.5 at 25 °C. 
Where possible, data was fit using MicroCal Origin 7 software and the Ka was averaged (levan 
polysaccharides – 3 independent experiments, levan digest – 2 independent experiments). The top 
half of each panel shows the raw injection heats and the bottom panel shows the integrated peak 
areas.  
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4.3.4.2 Cloning, expression, purification and crystallisation 
The surface glycan binding protein (SGBP) BT1761 is the only protein from the levan PUL 
outer membrane apparatus (Figure 4.1) which does not have a solved structure. BT1761SGBP was 
cloned without its Type II signal sequence into the E. coli expression vector pET28a. The construct 
was overexpressed in BL21 with an N-terminal Hisx6-tag and purified using IMAC (Figure 4.18A) 
followed by SEC. Eight 96-condition screens for crystal hits (Molecular Dimensions Structure, Index, 
PACT, Morpheus, JCSG 1/2/3/4) produced diffracting crystals in one condition; 0.1 M MES pH 5, 1.6 
M ammonium sulphate (Figure 4.18B). A dataset was collected at DLS however, there was no 
suitable complete model for MR. A partial solution for ~25 % of BT1761SGBP, to a resolution of 2.5 Å, 
was found using an edited model of a predicted glycan binding protein BT2081 (PDB ID: 3HBZ) 
produced by MrBUMP (Keegan and Winn, 2007). BT1761SGBP with selenomethionine incorporated 
produced crystals which did not diffract. A C-terminal Hisx6-tagged BT1761SGBP construct was also 
produced but did not crystallise.   
 
Figure 4.18 Purification and crystallisation of BT1761 surface glycan binding protein.  
A: Example SDS-PAGE of BT1761SGBP samples following overexpression in E. coli BL21 and 
IMAC purification. Cell free extract (CFE), flow through (FT), wash (W), elution with 5 mM 
imidazole (E5) and elution with 100 mM imidazole (E100). The major band at ~50kDa in CFE 
and E100 lanes is the expected MW of BT1761SGBP. Molecular weight (MW) marker shows 
approximate protein sizes in kDa. B: Crystal hit produced in 0.1 M MES pH 5, 1.6 M 
ammonium sulphate (Molecular Dimensions screen JCSG 4 condition G5).    
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 Lipoproteins such as SGBPs have N-terminal linker sequences between the lipid anchor and 
the globular protein domains (Cameron et al., 2012). All existing structures of recombinant 
lipoproteins from Bacteroides spp., expressed without the signal peptide, are lacking the first 15 – 20 
residues suggesting the linker region is disordered when the protein is not membrane associated 
and could interfere with crystal formation (Koropatkin et al., 2008; Cameron et al., 2012).  Linkers 
from BT2261LP, BT2262LP and BT2263SusD are clear in the BT2261-4 complex structure and are up to 
22 residues long (Chapter 3, Figure 3.8). Therefore a truncated construct without the first 22 N-
terminal residues was cloned into pB22 with a TEV-cleavable N-terminal Hisx7-tag. The protein was 
overexpressed in the periplasm of TUNER E. coli, purified using IMAC and the Hisx7-tag was cleaved 
before SEC. This construct only produced very small, irregular crystals. Addition of levan 
oligosaccharides (Figure 4.7) did not improve crystallisation of BT1761SGBP.     
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4.3.5 Levan Acquisition Outer Membrane Protein Complex BT1760-3 
Previous studies have suggested the lipoproteins expressed in Bacteroides PULs interact at 
the cell surface to form a multiprotein complex (Shipman et al., 2000; Foley et al., 2016; Cartmell et 
al., 2017). Certainly in the BT2261-4 purification the two downstream lipoproteins from the locus 
(BT2261LP and BT2262LP) formed a tight complex with the SusC, supporting this hypothesis.  
Depending on the strength and nature of these interactions, it may be possible to co-crystallise the 
entire outer-membrane complex of the levan utilisation system. This would give vital insights into 
the location of interaction sites on each protein component and level of co-operation between the 
binding, catalytic and import components of the system.  
Purification of BT1762-3 from cells grown on MM-Frc did not yield the auxiliary lipoproteins 
from the levan PUL (BT1760GH32 and BT1761SGBP). This is most likely to be because the cells were not 
actively degrading and importing levan so perhaps the proteins were not interacting. However, it 
was not possible to purify BT1762-3 from cells incubated with levan (section 4.3.2.1) therefore to 
gain insight into the overall complex co-crystalliation was utilised.    
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4.3.5.1 Crystallisation 
The mature proteins BT1760GH32 and BT1761SGBP, without signal peptides, were cloned into 
pET28a and overexpressed in BL21. The soluble recombinant proteins were purified using IMAC and 
size exclusion chromatography. These proteins (60 µM each) were mixed with freshly purified 
BT1762-3 (45 µM) and 2.5 mM levan oligosaccharides before incubation at room temperature for 1 
hour. Molecular Dimensions screens MemGold 1 and MemGold 2 were set up in sitting drop using a 
Mosquito robot. After 48 hours approximately 25 % of the 192 conditions screened had produced 
crystals (Figure 4.19). A dataset has not been collected from any of these crystals because none of 
those tested in-house diffracted sufficiently.  Therefore it is unknown how many of the proteins in 
the mixture are present in the crystals ie. if the crystals are multi-protein complexes or just single 
proteins or BT1762-3 etc. Crystals were harvested, for analysis of the component proteins by SDS-
PAGE, but the crystals were difficult to handle and disintegrated when washed.  
 
 
Figure 4.19 Crystallisation screen hits of B. 
theta levan acquisition BT1760-3 complex 
Crystals produced from a mixture 
containing approximately 60 µM 
BT1760GH32, 60 µM BT1761SGBP, 45 µM 
BT1762-3SusCD and 2.5 mM levan 
oligosaccharides. Crystallisation conditions; 
0.2 M NaCl, 0.05 M Calcium acetate pH 5, 
29 % (w/v) PEG 400 (top panel) and 0.04 M 
Magnesium chloride hexahydrate, 0.05 M 
NaCl, 0.1 M HEPES pH 7.5, 32 % (w/v) PEG 
400 (bottom panel). 
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4.3.5.2 Native Gel Analysis of the BT1760-3 Complex 
A blue native gel (Figure 4.20) was used to investigate the possible oligomerisation and 
interactions between the outer membrane proteins using the BT1760-3 mixture crystallised in Figure 
4.19. The individual components BT1760GH32, BT1761SGBP and BT1762-3SusCD were all prepared with 
detergent (0.5 % DDM) and used for comparison. The full BT1760-3 complex (lane C) showed four 
extra bands of higher MW than BT1762-3SusCD alone (Figure 4.20). These bands must be several 
proteins from the mixture interacting and forming complexes but the exact configuration is 
unknown. The size of each ‘complex’ band cannot be estimated because the highest MW protein 
standard is 320 kDa. Mass spectrometry could be used to identify the very high molecular weight 
bands. SEC was used by Bert van den Berg to analyse the mixture of proteins but did not indicate 
that complex formation was occurring as UV peaks were observed for the individual proteins.    
 
Figure 4.20 Native gel of BT1760-3 levan 
acquisition complex.  
Native-PAGE Bis-Tris 4-16 % polyacrylamide gel 
(ThermoFisher) showing the soluble components 
of the complex individually BT1760GH32 and 
BT1761SGBP, the SusCD pair BT1762-3 and the full 
BT1760-3 complex (C). All samples were prepared 
with detergent for comparison. MW shows 
approximate sizes in kDa for four membrane 
proteins. The 150 kDa protein standard Mep2 
appears as a diffuse band. 
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4.4 Discussion 
4.4.1 BT1762-3 Structures 
The overall BT1762-3 structures (Figure 4.4 and 4.9) show the same general configuration as 
BT2263-4; dimeric SusC homologues each covered with a SusD ‘lid’, with the interface between 
BT1762SusD and BT1763SusC involving the ligand binding face of the SusD (Figure 4.4D). This suggests 
the structure is conserved across SusCD homologue complexes. The conformation exposes the 
conserved TPR domains of BT1762SusD to the cell surface. TPRs domains are often involved in protein-
protein interactions and the assembly of multi-protein complexes therefore may form contacts with 
the levan PUL encoded lipoproteins BT1760GH32 and BT1761SGBPduring glycan import.  
The degradation of 30 kDa from the N-terminus of BT1763SusC was completely unexpected 
(Figure 4.4 and 4.5). The remainder of the barrel remained unaffected by the removal of the plug 
domain, which suggests the plug could come out of the barrel in its entirety to facilitate the 
transport of large substrates, a theory which has been the subject of much debate among the TBDT 
research field (Hickman et al., 2017).  
The BT1762-3 structure with levan oligosaccharides bound (Figure 4.9) is highly significant as 
the first SusCD homologue structure with glycan bound. The substrate is comprised of at least five 
fructose units with a possible sixth fructose forming a branch (Figure 4.21). the ligand is bound by 
thirteen residues; seven from BT1762SusD and six from BT1763SusC, Figure 4.11. The complex 
completely encloses the levan oligo suggesting there is a maximum size limit for import (Figure 
4.11A).    
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Figure 4.21 Structure and electron density of the levan oligogosaccharide bound by BT1762-3 
The BT1762-3 bound levan oligosaccharide consisting of a main chain of five fructose units (1-5) 
and a possible branch with one additional fructose molecule (6).  
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4.4.2 Single-channel electrophysiology of BT1762-3 
To investigate in vitro the findings of the MD simulations of BT2261-4, the spontaneous 
degradation of the BT1763SusC plug domain was exploited for single-channel electrophysiology. 
Purified protein was sent to collaborators at Jacobs University (Bremen, Germany) and the 
experiments were carried out by Satya Bhamidimarri.  
The proteins were all re-folded in vitro following SDS-PAGE which allowed BT1763SusC to be 
separated from BT1762SusD. Reconstitution of the full length BT1762-3 SusCD complex and full length 
BT1763SusC alone in a lipid bilayer generated very small, relatively stable currents (Figure 4.22). This is 
consistent with a relatively small channel and would be expected with a TBDT due to the plug 
domain occluding the channel. The complex lacking a plug domain, Δplug-BT1762-3SusCD, produced 
large channels with average conductance values approximately 1.5 nS. The noisy, unstable trace 
showed a wide range of conductance values, which indicated dynamic opening and closing of the 
channel. The truncated complex was separated using SDS-PAGE, Δplug-BT1763SusC was isolated from 
the gel and refolded before reconstitution in the bilayer. The resulting trace showed a large channel 
with conductance value around 3 nS with a stable current. This suggested that the extracellular 
loops of BT1763SusC were not responsible for the gating channel observed in the Δplug-BT1762-3SusCD 
protein.   
 
Figure 4.22 Single-channel electrophysiology of BT1762-3 complexes.  
BT1762-3SusCD complex and BT1763SusC alone tested with and without the plug domain (Δplug). 
Traces and histograms are representative of ten experiments. N represents the number of events, 
defined as the current value in a 200 µs window. Data obtained at +50 mV. Figure adapted from 
Glenwright et al. 2017.  
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4.4.3 Investigating the function of BT1762-3 
Single base mutagenesis of BT1762SusD indicates six of the seven binding residues are 
essential for binding of BT1762SusD in isolation to levan (Figure 4.12). Six residues from BT1763SusC 
complete the binding site. BT1762-3 cannot be purified in high enough quantities for ITC (20 mg per 
test) therefore a different method would be required to probe binding affinity of the whole complex 
for levan.  
Based on the ITC data of recombinant BT1762SusD W103A which showed that this residue 
was essential for levan binding, the W103A mutant was made in the genomic copy of BT1762 to 
produce the W103A-BT1762 strain. The lack of growth defect for this mutant strain on levan was 
somewhat unexpected (Figure 4.14) and may be due to the binding site of the complex being 
composed of multiple residues from both the SusD and the SusC, such that loss of a single residue 
does not prevent glycan import. In addition it may be that the BT1762-3 SusCD in the W103A-
BT1762 strain functions less efficiently than the WT, but that this reduced efficiency is 
masked/unable to be observed in the assay used.  
MD simulations of BT2261-4 showed the hinge loop (L7) moved with BT2263SusD providing 
most of the remaining BT2264SusC-BT2263SusD interactions in the open state, and underwent the 
biggest conformational change (Chapter 3, Figure 3.15B). The conserved loop was deleted in the 
genomic copy of BT1763SusC but surprisingly only caused a slightly increased lag-phase on MM-Levan 
(Figure 4.14). Therefore the BT1762SusD ‘lid’ must retain the ability to open/close without the hinge 
loop. The dynamic movement of BT1762SusD ‘lid’ may also involve a second loop L8 of BT1763SusC 
which is closely associated to the binding protein (Figure 4.9 and 4.23). Further mutations or 
deletions of the extracellular loops of BT1763SusC could be used to identify the essential contacts 
between the two proteins which allow the dynamic movement of BT1762SusD.  
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Figure 4.23 Structure of BT1762-3 highlighting extracellular loops 7 and 8 
Cartoon representation of BT1762-3 showing BT1762SusD in purple and BT1763SusC in dark blue. 
The hinge loop (L7) highlighted is yellow and the L8 loop is cyan. The N-terminal linker sequence 
of BT1762SusD which attaches to the lipid anchor is also highlighted.   
 
A knockout of the DUF4480 domain (ΔDUF-BT1763) cannot grow on MM-Levan after 48 
hours which suggests the domain is essential for BT1763SusC to transport levan (Figure 4.14). 
Expression tests of BT1762SusD and BT1763SusC show both proteins in the OM suggesting the 
phenotype is due to disrupted functioning of BT1763SusC rather than problems with expression 
(Figure 4.15). DUF4480 is present in ~80 % of SusC homologues from B. theta. The domain 
immediately precedes the TonB box (Figure 4.13B) which interacts with part of the inner membrane 
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TonB apparatus in the periplasm, providing energy for transport (Hickman et al., 2017). 
Consequently DUF4480 may also be involved in energy procurement.  
4.4.4 BT1761 surface glycan binding protein  
Binding of levan to BT1761SGBP measured by ITC confirms that it is a glycan binding protein 
with higher affinity for levan polysaccharides and oligosaccharides than BT1762SusD (Figure 4.17). 
SGBPs are thought to interact with and sequester the target glycan at the cell surface for 
degradation and subsequent import by other proteins from the PUL. This may be why the binding 
affinity of BT1761SGBP is higher than that of BT1762SusD.  Producing well diffracting crystals of 
BT1761SGBP was difficult; only one dataset has been collected, for which there is only a partial MR 
solution. To produce a structure anomalous x-ray scattering data will be required as SGBPs do not 
have sequence homology and finding structural homology is more challenging. Existing structures of 
SGBPs have several domains and the higher flexibility of multi domain proteins often reduces the 
chance of crystallisation (Cameron et al., 2012; Tauzin et al., 2016; Cartmell et al., 2017). This may 
explain the problems producing diffracting crystals of BT1761SGBP.  The heparin binding SGBP BT4661 
consists of six domains (Figure 4.24) (Cartmell et al., 2017).  
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Figure 4.24 Structure of BT4461 SGBP from the B. theta heparin PUL 
Cartoon representation of BT4661SGBP (PDB ID: 4AK1) coloured blue to red from the N-terminus to 
C-terminus. The six discrete domains are labelled (D1-6).  
 
4.4.5 Levan Acquisition Outer Membrane Protein Complex 
A recent study used live-cell super-resolution microscopy to show dynamic recruitment and 
assembly of a complex of proteins from the B. theta Starch Utilisation System (Karunatilaka et al., 
2014). Therefore, in this study, BT1760GH32, BT1761SGBP and BT1762-3SusCD were purified separately 
and mixed together to produce the OM levan acquisition complex. The native gel of all four 
components (BT1760-3) shows very large bands over 320 kDa which suggests the proteins were 
interacting in various combinations (Figure 4.20). Crystals produced from the mixture of proteins 
(Figure 4.19) did not diffract and SDS-PAGE analysis of the crystal components was unfortunately 
unsuccessful.  
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Chapter 5 – Final Discussion 
5.1 Structure of SusCD homologues 
This study presents the X-ray crystal structures of two functionally distinct SusCD complexes.  
The relative orientation of SusC and SusD homologues is the same in the two structures (Figure 5.1). 
BT1762-3 is a classical glycan importing SusC-like protein whereas BT2261-4 likely transports 
peptides suggesting this configuration could be conserved across SusCD homologues. SusC-like 
transporters only have ~20 % sequence homology with each other but this study suggests high 
structural homology. The dimeric conformation observed in both structures is unique among 
characterised TBDTS and was not a consequence of crystallisation (Noinaj et al., 2010). The 
transporters were shown to exist as dimers using mass spectrometry, analytical gel filtration and size 
exclusion chromatography multi-angle light scattering (SEC-MALS) (Glenwright et al., 2017).  
The ligand in each complex is bound at the SusCD interface and involves the highly variable 
SusD binding site (Figure 5.1). This conformation exposes the conserved TPR domains which were 
previously predicted to be the site of SusC-SusD interactions (Bolam and Koropatkin, 2012). TPRs 
have been linked with protein-protein interactions, therefore it is feasible that they could mediate 
interactions between the SusD-likes and the auxiliary surface lipoproteins expressed from the same 
PUL. The peptide and levan oligosaccharide are completely enclosed within their respective 
complexes, which suggests a size limit for import by SusC homologues. This may explain the 
requirement of most PULs to have a functional surface-exposed endo-acting enzyme to degrade the 
target glycan into small enough oligosaccharides for import (Bolam and Sonnenburg, 2011). 
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Figure 5.1 Overall architecture of SusCD complexes 
Cartoon representation of the SusCD complexes from the side within the OM. A: BT2261-4 with 
the bound peptide shown as black spheres. B: BT1762-3 with the bound levan oligosaccharide 
shown as black spheres.  
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Purifying proteins directly from the B. theta OM was very advantageous and allowed the 
complexes to remain intact. The association of SusC and SusD homologues within the OM had been 
predicted previously, but the interactions observed here were robust enough to withstand several 
rounds of purification with strong detergent. BT2261-4 included two auxiliary lipoproteins which 
also remained closely associated with the SusCD pair (Figure 5.1). In comparison, BT1762-3 did not 
co-purify with the other OM lipoproteins from the PUL (BT1760GH32 and/or BT1761SGBP), this could be 
because the complex was not actively processing and importing levan therefore the OM components 
were not interacting when the cells were harvested (Figure 5.1). Perhaps the interactions between 
BT1762-3 and the other proteins were not strong enough to maintain the complex during 
purification because the complex formation may be more dynamic than those observed in BT2261-4.    
5.2 Mechanism of Import 
The ligand binding site is excluded from solvent, indicating the SusD-like binding protein 
must move away from the transporter to bind substrate from the environment. MD simulations 
showed the complex remained closed when the peptide ligand was present (Figure 3.15). However, 
during most of the apo-complex simulations BT2263SusD moved in a hinge-like motion away from 
BT2264SusC to expose the ligand binding site (Figure 3.15). This opening/closing dynamic was 
supported in vitro by the single-channel electrophysiology of BT1762-3 which exploited the 
spontaneous degradation of the plug domain (Figure 4.22).  
BT2264SusC loop L7 moves with BT2263SusD in the MD simulations and was required for most 
of the remaining BT2264SusC-BT2263SusD interactions in the open state. The subsequently named 
‘hinge loop’ is conserved in the BT1763SusC structure, which suggests it could be important for SusC 
function (Figure 5.2A and B). Surprisingly though, a mutant strain lacking the hinge loop of 
BT1763SusC (ΔHinge-BT1763) showed very little growth defect on levan (Figure 4.15). These data 
indicate that the function of the complex was mostly unaffected by the loss of the hinge loop and 
retained the ability to open/close. Therefore a different loop or region could be important in 
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BT1762-63 and possibly BT2263-64 function. Inspection of the SusC structures reveals a second 
conserved loop (L8) that could act as a hinge point and it may be that this loop is actually the key 
critical hinge point between the SusC and SusD, or is able to compensate for the loss of the L7 loop 
(Figure 5.2A and B). This loop could also be removed and function of the complex could be verified 
by growing the strain on levan (as with hinge loop L7 in Figure 4.15).   
In both complete SusCD structures the N-terminal TonB box is not visible which is consistent 
with the theory that the domain is flexible, when substrate is bound, to interact with TonB across 
the periplasm (Hickman et al., 2017). The N-terminal plug domain, which is conserved between 
TBDTs, is very similar in size, structure and position in the two SusC homologues. However, the long 
plug loop of BT2264SusC which interacts with the peptide (via Leu120) is not present in BT1763SusC 
(Figure 5.2C). The two ligands are bound in the same relative location but the equivalent loop is not 
present in the BT1763SusC structure. This contradicts the idea, explored in Chapter 3 (Figure 3.16), 
that the interaction between the ligand and plug loop provides the signal to TonB that the binding 
site is occupied thus instigating the transport cycle.       
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Figure 5.2 Close-up overlays of BT2264SusC and BT1763SusC  
A: Overlay of BT2264SusC (yellow) and BT1763SusC (blue) from the side showing the conserved hinge 
loop (L7) in green (BT2264) and purple (BT1763). Loop 8 is shown in cyan (BT2264) and red 
(BT1763). Helices are shown as cylinders. B: Overlay of BT2264SusC and BT1763SusC (blue) from the 
outside of the cell (coloured as in A). C: Overlay of the plug domains of of BT2264SusC (yellow) and 
BT1763SusC (blue). The bound peptide ligand is shown as magenta sticks and the levan 
oligosaccharide is shown as green sticks. The plug loop of BT2264SusC is highlighted and Leucine 
120 is shown in orange. 
 
  
136 
 
Research into SusC-like transporters is just beginning. B. theta encodes 103 predicted SusCD 
homologues of which approximately 20 are expressed as part of characterised PULs. The successful 
native expression and subsequent purification of two SusCD homologues from B. theta has opened 
up a new avenue for studying highly expressed outer membrane proteins from the Bacteroides spp. 
Questions which remain include, what is the absolute size limit for import by a SusC TBDT? Can 
heavily branched oligosaccharides be imported? PULs which target highly complex glycans often 
encode multiple SusCD homologues, so does each transporter target different oligosaccharides from 
the glycan? Crystal structures of further ligand-bound SusCD homologues would be invaluable for 
answering these questions.  
Regarding the function of the complexes; what is the purpose of the essential DUF4480? 
Why is the domain only present in ~80% of SusC-like transporters? The open/close mechanism of 
the SusD ‘lid’ does not appear to require the Hinge loop as predicted, therefore how much contact is 
required between the SusC and SusD homologues? Would removing further loops disrupt the 
system? Which binding residues are required for the complex recognise the substrate? Mutation of 
the BT1762-3 complex, which must be functional for growth of B. theta on levan, could possibly 
answer these questions and more.    
Finally, what is the rate of transport by SusC-like proteins? Some PULs have been shown to 
lose oligosaccharides at the cell surface which are then scavenged by other members of the HGM 
(Rogowski et al., 2015). This would suggest the rate of oligosaccharide production by the endo-
acting enzymes is significantly faster than the rate of import in such systems. . The rate of transport 
by TBDTs remains unknown because of the inherent difficulty of studying a system which requires 
two membranes.  
Glycan use by the HGM is a key factor driving community composition so studies which 
reveal the mechanism used by the HGM to access their major nutrient sources are important for 
understanding HGM-host symbiosis and the role it plays in human health. This work has addressed 
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some of the questions regarding the mechanism of nutrient import by Sus-like systems but many 
questions remain.  
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Appendix A: Primer List 
All primers used in this study are listed in the table below (Table A). 
Construct Fwd/
Rev 
Sequence 5'-3' Restr. 
site 
SLIC 
pET28a BT2262 F CTCCATATGTGCGACAAATCAACAGATGAC NdeI No  
R CTCCTCGAGTTATTATTGTTTTACTATAATGTC XhoI No 
pET9 BT2262 F TACTTCCAATCCATGACGTTGGAAAGAGAGGGTGAT - Yes  
R TATCCACCTTTACTGTTATTATTGTTTTACTATAATGTCAAAAG
A 
- Yes 
pET28a BT2263 F CTCGCTAGCGGTTGCGACCTGAACATC NheI No  
R CTCCTCGAGTTACTATTTGATATCCCACCA XhoI No 
pET9 BT2263 F TACTTCCAATCCATGGTGACGGCGGATTTGATATTCC - Yes  
R TATCCACCTTTACTGTTATTATTTGATATCCCACCAAACCGGA
GT 
- Yes 
pExchange FLAG-tag 
BT2263 
F1 AAAGAAGATAACATTCGAGTCGACGTGGGATACGGGTGA SalI Yes 
 
R1 CTATTTGTCGTCATCGTCTTTGTAGTCAGCAGCAGCAGCTTTG
ATATCCCACCA  
- - 
 
F2 GCTGCTGCTGCTGACTACAAAGACGATGACGACAAATAGTAA
CCAATAACTTAG  
- - 
 
R2 CACCGCGGTGGCGGCCGCTCTAGACAGTTTATATTCCCA  XbaI Yes 
FLAG-tag screen F GCTGCTGCTGCTGACTACAAAGACGATGACGACAAATAG - - 
pExchange BT2264 
ko 
F1 AAAGAAGATAACATTCGAGTCGACCAAAAGCTGCTGGGA SalI Yes 
 
R1 ATGATGCATATAATAATCCGATGTACGAAATTTG  - -  
F2 CAAATTTCGTACATCGGATTATTATATGCATCAT  - -  
R2 GGTGGCGGCCGCTCTAGAGATAGAGTAATCAAT  XbaI Yes 
pET28a CT His 
BT1761  
F TAAGAAGGAGATATACCATGGGCAGTGATGACTTCAAATCC NcoI Yes 
 
R GTGGTGGTGGTGGTGCTCGAGTTTACACAAGTAGTTGATTG XhoI Yes 
pET28a NT His 
BT1761 
F GTGCCGCGCGGCAGCCATATGAGTGATGACTTCAAATCC NdeI Yes 
 
R GTGGTGGTGGTGGTGCTCGAGTTATTTACACAAGTAGTTGAT
TG 
XhoI Yes 
pB22 NT-22res. 
trunc. BT1761 
F TTATATTTTCAAGGTCTCGAGGAATACGCAGGAACTGTCGAC  XhoI Yes 
 
R AGCGGGTGTGAATACTCTAGATTATTTACACAAGTAGTTGAT
TG 
XbaI Yes 
pExchange CT 6xHis-
tag BT1763 
F1 CTCGTCGACGGTAACGACAATATCAAATGG SalI No 
 
R1 TTAGTGGTGGTGGTGGTGGTGAAATCCGATGTTAAGTCCGAA - -  
F2 CACCACCACCACCACCACTAACTTACTTCATCAATAAAACGA - -  
R2 CTCTCTAGACTGGCTCGGCTTGTGGAAGTC XbaI No 
pExchange CT 4xAla 
6xHis-tag BT1762 
F1 AAAGAAGATAACATTCGAGTCGACTGCCCTTACCGGAATCAA
C 
SalI Yes 
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R1 TTAGTGGTGGTGGTGGTGGTGAGCAGCAGCAGCCCAACCGA
AATTCTGTGT 
- Yes 
 
F2 GCTGCTGCTGCTCACCACCACCACCACCACTAACTAACCATCT
TAAAACAA  
- Yes 
 
R2 CACCGCGGTGGCGGCCGCTCTAGATCTTCGTTTCCTCCCCAG  XbaI Yes 
His-tag screen R GTGGTGGTGGTGGTGGTG - - 
Internal BT1762 
sequencing 
F CTGTTCCATTCGAACAGATC - - 
pExchange Hinge 
20res BT1763 
F1 AAAGAAGATAACATTCGAGTCGACACAATCTTTCCGTCAGCA  SalI Yes 
 
R1 TTTGAAACCACCAGGTGCATAGATAGTATAACGGGC - -  
F2 TATGCACCTGGTGGTTTCAAACGCAACCAGATCGGT - -  
R2 CACCGCGGTGGCGGCCGCTCTAGAGATCATTCGTTTTATTGA  XbaI Yes 
Hinge mutation 
sequencing 
F CTCTCCGTCGGGACGGTTC - - 
pExchange W103A 
BT1762 
F1 AAAGAAGATAACATTCGAGTCGACGAAGAGTGTAGTCGGAC
ATAC 
SalI Yes 
 
R1 ATTGATATTCGCGTCGGTGGTATTGATACC  - -  
F2 ACCACCGACGCGAATATCAATGATATATGG  - -  
R2 CACCGCGGTGGCGGCCGCTCTAGACTGAATCAGTGCTTCGGC
AC 
XbaI Yes 
W103A sequencing F CTACGCCATCTGGGCGAC - - 
pExchange BT1763 
DUF4480 ko 
F1 AAAGAAGATAACATTCGAGTCGACCTACGGGAGCATG SalI Yes 
 
R1 AACTTCATCTACCATCTGAATGTTTTGCCCCCACAG  - -  
F2 CTGTGGGGGCAAAACATTCAGATGGTAGATGAAGTT  - -  
R2 GGTGGCGGCCGCTCTAGAGAGGGTTACGACGGT XbaI Yes 
DUF ko sequencing F CTGGTATCATGAAGAACA - - 
     
BT1762SusD Site Directed Mutagensis 
BT1762 D59A/N61A F GCGACAGGTGATGCAATCGCATCTTCCTTCTCT     
R AGAGAAGGAAGATGCGATTGCATCACCTGTCGC    
BT1762 D59A F GCGACAGGTGATGCAATCAACTCTTCCTTCTCT     
R AGAGAAGGAAGAGTTGATTGCATCACCTGTCGC    
BT1762 N61A F GCGACAGGTGATGATATCGCATCTTCCTTCTCT     
R AGAGAAGGAAGATGCGATATCATCACCTGTCGC    
BT1762 D85A F TCGGGAACAGAAGCAGGCGGTGTGTTC     
R GAACACACCGCCTGCTTCTGTTCCCGA    
BT1762 C316A F CAGATACTGGGCGCATGCGACTTCCAC    
R GTGGAAGTCGCATGCGCCCAGTATCTG   
BT1762 R386A F GATGACTGGAGCGCAAGCAAGGGACTT    
R AAGTCCCTTGCTTGCGCTCCAGTCATC   
BT1762 Y413A F AAGAAAGGTTCTGCATGGGCCAGTTCT     
R AGAACTGGCCCATGCAGAACCTTTCTT    
Table A Primers used in this study. Sewing PCR requires two set of primers labelled F1/R1 and 
F2/R2.  
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Appendix B: Protein Structure PDB codes  
All PDB codes of the structures produced in this study are listed in the table below (Table B). 
Protein Structure Expression PDB code Resolution 
BT2262 Soluble – E. coli 5FQ3 3.1 Å 
BT2263 Soluble – E. coli 5FQ4 1.9 Å 
BT2261-4 Native, membrane – B. theta 
5FQ6 2.8 Å 
5FQ7 3.4 Å 
5FQ8 2.75 Å 
BT1762-3 Apo Native, membrane – B. theta 
5T3R 3.1 Å 
5T4Y 3.1 Å 
BT1762-3 with levan 
oligosaccharide bound 
Native, membrane – B. theta 
N/A 
Not deposited/unpublished 
2.9 Å 
Table B Protein Structure PDB codes. All protein structures produced in this study, listed with 
expression details and PDB codes. 
